View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 24, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Amgen Inc.
Entity Central Index Key	0000318154
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		637,219,244

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenues	$ 5,904	$ 5,773	$ 17,517	$ 17,047
Operating expenses:
Cost of sales	1,037	990	3,005	3,010
Research and development	926	877	2,555	2,519
Selling, general and administrative	1,293	1,170	3,773	3,443
Other	325	297	303	347
Total operating expenses	3,581	3,334	9,636	9,319
Operating income	2,323	2,439	7,881	7,728
Interest expense, net	355	325	1,040	972
Interest and other income, net	126	267	519	627
Income before income taxes	2,094	2,381	7,360	7,383
Provision for income taxes	235	360	894	1,140
Net income	$ 1,859	$ 2,021	$ 6,466	$ 6,243
Earnings per share:
Basic (in usd per share)	$ 2.88	$ 2.78	$ 9.67	$ 8.52
Diluted (in usd per share)	$ 2.86	$ 2.76	$ 9.61	$ 8.46
Shares used in calculation of earnings per share:
Basic (in shares)	645	728	669	733
Diluted (in shares)	649	733	673	738
Dividends paid per share (in usd per share)	$ 1.32	$ 1.15	$ 3.96	$ 3.45
Product sales [Member]
Revenues:
Product sales	$ 5,510	$ 5,453	$ 16,532	$ 16,226
Other revenues [Member]
Revenues:
Total revenues	$ 394	$ 320	$ 985	$ 821

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 1,859	$ 2,021	$ 6,466	$ 6,243
Other comprehensive income (loss), net of reclassification adjustments and taxes:
(Losses) gains on foreign currency translation	(71)	41	(153)	100
Gains (losses) on cash flow hedges	41	(50)	270	(324)
Gains (losses) on available-for-sale securities	97	9	(237)	247
Other	(3)	6	(1)	5
Other comprehensive income (loss), net of taxes	64	6	(121)	28
Comprehensive income	$ 1,923	$ 2,027	$ 6,345	$ 6,271

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 11,956	$ 3,800
Marketable securities	17,965	37,878
Trade receivables, net	3,441	3,237
Inventories	3,017	2,834
Other current assets	1,941	1,727
Total current assets	38,320	49,476
Property, plant and equipment, net	4,899	4,989
Intangible assets, net	7,782	8,609
Goodwill	14,684	14,761
Other assets	1,648	2,119
Total assets	67,333	79,954
Current liabilities:
Accounts payable	1,042	1,352
Accrued liabilities	6,313	6,516
Current portion of long-term debt	5,077	1,152
Total current liabilities	12,432	9,020
Long-term debt	29,350	34,190
Long-term deferred tax liabilities	978	1,166
Long-term tax liabilities	8,832	9,099
Other noncurrent liabilities	1,392	1,238
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 640.5 shares in 2018 and 722.2 shares in 2017	31,145	30,992
Accumulated deficit	(15,987)	(5,072)
Accumulated other comprehensive loss	(809)	(679)
Total stockholders’ equity	14,349	25,241
Total liabilities and stockholders’ equity	$ 67,333	$ 79,954

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750.0	2,750.0
Common stock and additional paid-in capital, shares outstanding	649.0	722.2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net income	$ 6,466	$ 6,243
Depreciation and amortization	1,456	1,506
Share-based compensation expense	224	244
Deferred income taxes	(294)	(379)
Other items, net	412	381
Changes in operating assets and liabilities, net of acquisition:
Trade receivables, net	(234)	(229)
Inventories	(93)	(54)
Other assets	(110)	(110)
Accounts payable	(311)	(50)
Accrued income taxes, net	(384)	48
Long-term tax liabilities	204	314
Other liabilities	766	251
Net cash provided by operating activities	8,102	8,165
Cash flows from investing activities:
Purchases of marketable securities	(12,617)	(26,661)
Proceeds from sales of marketable securities	28,059	18,580
Proceeds from maturities of marketable securities	3,881	4,765
Cash acquired in acquisition, net of cash paid	197	0
Purchases of property, plant and equipment	(513)	(511)
Other	(31)	(119)
Net cash provided by (used in) investing activities	18,976	(3,946)
Cash flows from financing activities:
Net proceeds from issuance of debt	0	3,485
Repayment of debt	(500)	(4,405)
Net change in commercial paper	0	1,499
Repurchases of common stock	(15,670)	(2,371)
Dividends paid	(2,667)	(2,531)
Other	(85)	(137)
Net cash used in financing activities	(18,922)	(4,460)
Increase (decrease) in cash and cash equivalents	8,156	(241)
Cash and cash equivalents at beginning of period	3,800	3,241
Cash and cash equivalents at end of period	$ 11,956	$ 3,000

Summary of significant accounting policies	9 Months Ended
Summary of significant accounting policies	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Basis of presentation The financial information for the three and nine months ended September 30, 2018 and 2017, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2017, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2018 and June 30, 2018. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.0 billion and $7.6 billion as of September 30, 2018 and December 31, 2017, respectively. Revenues Adoption of new revenue recognition standard In May 2014, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of January 1, 2018, by applying the modified-retrospective method to those contracts that were not completed as of that date. The results for reporting periods beginning after January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See Note 1, Summary of significant accounting policies, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017. Upon adoption, we recorded a net decrease of $25 million to Accumulated deficit due to the cumulative impact of adopting the new standard—with the impact related primarily to the acceleration of deferred revenue, net of related deferred tax impact. The adoption of this new standard had an immaterial impact on our reported total revenues and operating income as compared to what reported amounts would have been under the prior standard, and we expect the impact of adoption in future periods to also be immaterial. Our accounting policies under the new standard were applied prospectively and are described below. See Note 4, Revenues. Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales. Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Taxes collected from customers and remitted to government authorities and that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative expenses in the Condensed Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty estimates are based on historical and forecasted sales trends. Corporate partner revenues are composed primarily of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the research and development (R&D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&D services, (iii) manufacturing services, and/or (iv) commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur. Other recently adopted pronouncements In January 2016, the FASB issued a new accounting standard that amends the accounting and disclosures of financial instruments, including a provision requiring that equity investments (except for investments accounted for under the equity method of accounting) be measured at fair value, with changes in fair value recognized in current earnings. With the exception of equity investments that were previously accounted for at cost, a modified-retrospective approach was used to reflect the cumulative effect of adoption as an adjustment to Accumulated deficit as of the beginning of the fiscal year. The new standard will be applied prospectively to investments that were previously accounted for at cost. Upon adoption, on January 1, 2018, we recorded an immaterial adjustment to Accumulated deficit from Accumulated other comprehensive income (loss) (AOCI), which represented the net unrealized gain on all equity investments with a readily determinable fair value as of December 31, 2017. The impact that this new standard has on our Condensed Consolidated Statements of Income after adoption will depend on changes in fair values of equity securities in our portfolio in the future. See Note 8, Investments. In October 2016, the FASB issued a new accounting standard that amends the income tax accounting guidance for intra-entity transfers of assets other than inventory. The new standard requires that entities recognize the income tax consequences of an intercompany transfer of an asset, other than inventory, in the period the transfer occurs. The current exception to defer the recognition of any tax impact on intercompany transfers of inventory until the inventory is sold to a third party remains unaffected. We adopted this standard as of January 1, 2018, and will apply it prospectively to any transaction occurring on or after the adoption date. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, however the impact on our condensed consolidated financial statements in future periods will depend on the facts and circumstances of future transactions. In January 2017, the FASB issued a new accounting standard that changes the definition of a business to assist entities with the evaluation of when a set of assets acquired or disposed of should be considered a business. The new standard requires that an entity evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets; if so, the set of assets would not be considered a business. The new standard also requires that a business include at least one substantive process, and it narrows the definition of outputs. We adopted this standard as of January 1, 2018, and will apply it prospectively. Adoption of this new standard may result in more transactions being accounted for as asset acquisitions versus business combinations; however, the impact on our condensed consolidated financial statements in future periods will depend on the facts and circumstances of future transactions. In August 2017, the FASB issued a new accounting standard that amends the accounting and reporting of hedging activities, which we elected to adopt early during the second quarter of 2018. Among its provisions, the new standard (i) eliminates the separate measurement and reporting of hedge ineffectiveness and (ii) permits an entity to recognize in earnings the initial fair value of an excluded component of a hedging instrument’s fair value under a systematic and rational method over the life of the derivative instrument. In accordance with the transition provisions of the new standard, the separate measurement of ineffectiveness for our cash flow hedging instruments existing as of the date of adoption is required to be eliminated through a cumulative-effect adjustment to Accumulated deficit as of January 1, 2018, the beginning of the fiscal year. The ineffective portions of our cash flow hedges were not material to our previously issued condensed consolidated financial statements. In addition, certain provisions in the guidance require modifications to existing presentation and disclosure requirements on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 14, Derivative instruments. In March 2018, the FASB issued a new accounting standard to incorporate U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 118 (SAB 118), which addresses accounting implications of major tax reform legislation Public Law No. 115-97, commonly referred to as the Tax Cuts and Jobs Act (the 2017 Tax Act), enacted on December 22, 2017. SAB 118 allows an entity to record provisional amounts during a measurement period not to extend beyond one year from the enactment date and was effective upon issuance. We continue to analyze the 2017 Tax Act and in certain areas have made reasonable estimates of the effects on our condensed consolidated financial statements and tax disclosures. See Note 5, Income taxes. Other recent accounting pronouncements In February 2016, the FASB issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize on the balance sheet the assets and liabilities that arise from leases, including leases classified as operating leases under current GAAP, and disclose qualitative and quantitative information about leasing arrangements. The new standard requires a modified-retrospective approach to adoption and is effective for interim and annual periods beginning on January 1, 2019, but may be adopted earlier. In July 2018, the FASB further amended this standard to allow for a new transition method that provides the option to use the effective date as the date of initial application. We intend to elect this alternative transition method and therefore will not adjust comparative-period financial information. In addition, we intend to elect the package of practical expedients permitted under the transition guidance of the new standard to not reassess prior conclusions related to contracts that are or that contain leases, lease classification and initial direct costs. We expect to adopt this standard beginning in the first quarter of 2019. We do not expect that this standard will have a material impact on our Condensed Consolidated Statements of Income, but we do expect that upon adoption, it will have a material impact on our assets and liabilities on our Condensed Consolidated Balance Sheets. The primary effect of adoption will be the requirement to record right-of-use assets and the corresponding present value of lease obligation liabilities for current operating leases. The actual impact will depend on our lease portfolio at the time of adoption. In addition, the standard requires that we update the systems, processes and controls we use to track, record and account for our lease portfolio. We have selected a lease accounting information system, engaged third-party consultants and are progressing through system implementation. System readiness, including the implementation and functionality of software procured from third-party providers, is essential to enable preparation of the financial information required for this standard. In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020, but may be adopted earlier, beginning on January 1, 2019. With certain exceptions, adjustments are to be applied by using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.

Restructuring	9 Months Ended
Restructuring	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In 2014, we initiated a restructuring plan to invest in continuing innovation and the launch of our new pipeline molecules, while improving our cost structure. As part of the plan, we closed facilities in Washington State and Colorado and are reducing the number of buildings we occupy at our headquarters in Thousand Oaks, California, as well as at other locations. We estimate that we will incur $800 million to $850 million of pretax charges in connection with our restructuring, including (i) separation and other headcount-related costs of $540 million to $560 million with respect to staff reductions and (ii) asset-related charges of $260 million to $290 million that consist primarily of asset impairments, accelerated depreciation and other related costs resulting from the consolidation of our worldwide facilities. Through September 30, 2018, we incurred $547 million of separation costs and other headcount-related costs and $251 million of net asset-related charges. The amounts related to the restructuring recorded in the Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2018 and 2017, were not significant. As of September 30, 2018, the total restructuring liability was not significant.

Business combinations

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

Business combinations

Kirin-Amgen, Inc.

During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin-Amgen, Inc. (K-A), from Kirin Holdings Company, Limited (Kirin), making K-A a wholly owned subsidiary of Amgen. Upon its acquisition, K-A’s operations have been included in our condensed consolidated financial statements commencing on the share acquisition date. The acquisition relieved Amgen of future royalty obligations to K-A.

K-A is a corporation that was established in 1984 as a 50-50 joint venture with Kirin to fund the global development of EPOGEN^® (epoetin alfa). Over time, the scope of the collaboration was expanded to also include the products NEUPOGEN^® (filgrastim), Neulasta^® (pegfilgrastim), Aranesp^® (darbepoetin alfa), Nplate^® (romiplostim) and brodalumab. K-A held the intellectual property for each of these products and licensed the associated marketing rights in Asia to Kyowa Hakko Kirin (KHK), Kirin’s pharmaceutical subsidiary, and in most other territories to Amgen. In return, Amgen and KHK paid royalties to K-A, and K-A reimbursed Amgen and KHK’s R&D expenses. K-A had also given Johnson & Johnson (J&J) exclusive licenses to manufacture and market recombinant human erythropoietin for all geographic areas of the world outside the United States, China and Japan. Under this agreement, J&J pays royalties to K-A based on product sales.

Prior to the share acquisition date, we owned 50% of K-A and accounted for our interest in K-A by using the equity method of accounting, which included recording our share of K-A’s profits or losses in Selling, general and administrative expenses in the Condensed Consolidated Statements of Income. The carrying value of our equity method investment in K-A was $570 million as of December 31, 2017, and is included in Other assets in the Condensed Consolidated Balance Sheets.

The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K-A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million, which was recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income.

The primary means of consideration for this transaction was a payment of $780 million in cash. The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen’s preacquisition investment consisted of the following (in millions):



	Amount
Total cash paid to Kirin	$	780
Fair value of contingent consideration obligation	45
Loss on settlement of preexisting relationship	(168		)
Total consideration transferred to acquire K-A	657

Fair value of Amgen’s investment in K-A	825
Total acquisition date fair value	$	1,482

In connection with this acquisition, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date.

The fair values of assets acquired and liabilities assumed included cash of $977 million, licensing rights of $470 million, deferred tax liabilities of $102 million, other assets and liabilities of $131 million and goodwill of $6 million. The estimated fair value of acquired licensing rights was determined by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the assets. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted-average period of four years by using the straight-line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities represents primarily receivables for royalties earned by K-A but not yet received, offset partially by payables representing R&D expenses incurred but not yet reimbursed by K-A.

Pro forma results of operations for this acquisition have not been presented because this acquisition is not material to our consolidated results of operations.

Revenues

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Revenues

Revenues by product and by geographic area

We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold principally in Europe. Revenues were as follows (in millions):



	Three months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	$	1,242	$	50	$	1,292	$	1,309	$	54	$	1,363
Neulasta^®	897		154		1,051		977		146		1,123
Prolia^®	354		178		532		298		166		464
Aranesp^®	248		229		477		285		231		516
XGEVA®	323		110		433		282		105		387
Sensipar^® / Mimpara^®	330		79		409		373		84		457
EPOGEN^®	252		—		252		264		—		264
Other products	614		450		1,064		509		370		879
Total product sales⁽¹⁾	$	4,260	$	1,250	$	5,510	$	4,297	$	1,156	$	5,453
Other revenues					394						320
Total revenues⁽²⁾					$	5,904					$	5,773



	Nine months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	$	3,544	$	155	$	3,699	$	3,838	$	172	$	4,010
Neulasta^®	2,854		452		3,306		2,962		458		3,420
Prolia^®	1,070		566		1,636		903		491		1,394
Aranesp^®	714		689		1,403		851		711		1,562
XGEVA®	994		336		1,330		872		312		1,184
Sensipar^® / Mimpara^®	1,069		257		1,326		1,052		253		1,305
EPOGEN^®	746		—		746		826		—		826
Other products	1,783		1,303		3,086		1,474		1,051		2,525
Total product sales⁽¹⁾	$	12,774	$	3,758	$	16,532	$	12,778	$	3,448	$	16,226
Other revenues					985						821
Total revenues⁽²⁾					$	17,517					$	17,047

^____________


⁽¹⁾	Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2018 and 2017.


⁽²⁾	Prior-period amounts are not adjusted under the modified-retrospective method of adoption.

Financing and payment

Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.

Optional exemptions

We do not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for the services performed.

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The effective tax rates for the three and nine months ended September 30, 2018, were 11.2% and 12.1%, respectively, compared with 15.1% and 15.4%, respectively, for the corresponding periods of the prior year. The decrease in our effective tax rate for the three and nine months ended September 30, 2018, was due primarily to the impacts of U.S. corporate tax reform. On December 22, 2017, the United States enacted the 2017 Tax Act, which imposes a repatriation tax on accumulated earnings of foreign subsidiaries, implements a hybrid territorial tax system together with a current tax on certain foreign earnings and lowers the general corporate income tax rate to 21%. In March 2018, the FASB issued a new accounting standard to incorporate SAB 118, which permits us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. We continue to analyze the 2017 Tax Act and in certain areas have made reasonable estimates of the effects on our condensed consolidated financial statements and tax disclosures. The 2017 Tax Act includes U.S. taxation on certain foreign earnings, referred to as Global Intangible Low-Taxed Income (foreign intangible income), effective January 1, 2018. The FASB allows an entity to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as foreign intangible income in future years or provide for the tax expense related to the foreign intangible income as a period expense in the year it is incurred. We have recorded no provisional amount for deferred taxes on foreign intangible income because more time is needed to analyze the data in order to make an accounting policy election. We consider our key estimates on the repatriation tax, the net deferred tax remeasurement, the impact on our unrealized tax benefits and the accounting policy election on temporary basis differences related to foreign intangible income to be incomplete due to our continuing analysis of final year-end data and tax positions. We are still accumulating and processing data to update our underlying calculations, and we expect the U.S. Treasury and regulators may issue further guidance, among other things; therefore, our estimates may change during 2018. However, we expect to complete our analysis within the measurement period. The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and the interpretation of the relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. On November 29, 2017, we received a modified RAR that revised the IRS calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and are pursuing resolution through the IRS administrative appeals process, which we believe will likely not be concluded within the next 12 months. Final resolution of the IRS audit could have a material impact on our results of operations and cash flows if not resolved favorably, however, we believe our income tax reserves are appropriately provided for all open tax years. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. We are currently under examination by a number of other state and foreign tax jurisdictions. During the three and nine months ended September 30, 2018, the gross amounts of our unrecognized tax benefits (UTBs) increased $70 million and $225 million, respectively, as a result of tax positions taken during the current year. The UTB balance decreased by approximately $50 million during the third quarter of 2018 due to a state tax audit settlement. Substantially all of the UTBs as of September 30, 2018, if recognized, would affect our effective tax rate.

Earnings per share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Earnings per share

The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs, as determined by using the treasury stock method (collectively, dilutive securities).

The computations for basic and diluted EPS were as follows (in millions, except per-share data):



	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Income (Numerator):
Net income for basic and diluted EPS	$	1,859	$	2,021	$	6,466	$	6,243

Shares (Denominator):
Weighted-average shares for basic EPS	645		728		669		733
Effect of dilutive securities	4		5		4		5
Weighted-average shares for diluted EPS	649		733		673		738

Basic EPS	$	2.88	$	2.78	$	9.67	$	8.52
Diluted EPS	$	2.86	$	2.76	$	9.61	$	8.46

For the three and nine months ended September 30, 2018 and 2017, the number of anti-dilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Collaborations	9 Months Ended
Collaborations	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	Collaborations A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity. From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized for these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. The following describes a significant arrangement that had a material change since the filing of our Annual Report on Form 10-K for the year ended December 31, 2017. Novartis AG In April 2017, we expanded our existing migraine collaboration with Novartis AG (Novartis). In the United States, Amgen and Novartis jointly develop and collaborate on the commercialization of Aimovig^®(erenumab-aooe). Amgen, as the principal, recognizes product sales of Aimovig^® in the United States, shares U.S. commercialization costs with Novartis and pays Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig^®and other specified migraine programs. Novartis pays Amgen double-digit royalties on net sales of the products in the Novartis exclusive territories and funds a portion of global R&D expenses. As a result of certain regulatory and commercial events, we received milestone payments from Novartis of $147 million and $295 million during the three and nine months ended September 30, 2018, respectively, and $60 million during the three months ended September 30, 2017, which were recorded in Other revenues in the Condensed Consolidated Statements of Income. In addition, Novartis will make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds are achieved with respect to Aimovig^® in the United States. Amgen manufactures and supplies Aimovig^® worldwide. The migraine collaboration will continue for the commercial lives of the products unless terminated in accordance with its terms.

Investments

9 Months Ended

Sep. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Investments

Available-for-sale investments

The amortized cost, gross unrealized gains, gross unrealized losses and fair values of available-for-sale investments by type of security were as follows (in millions):



Types of securities as of September 30, 2018	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair values
U.S. Treasury notes	$	2,710	$	—	$	(84	)	$	2,626
U.S. Treasury bills	5,376		—		—			5,376
Other government-related debt securities:
U.S.	112		—		(3		)	109
Foreign and other	1,048		1		(41		)	1,008
Corporate debt securities:
Financial	2,786		—		(89		)	2,697
Industrial	2,654		4		(80		)	2,578
Other	594		—		(21		)	573
Residential-mortgage-backed securities	1,524		—		(62		)	1,462
Other mortgage- and asset-backed securities	490		—		(17		)	473
Money market mutual funds	8,955		—		—			8,955
Other short-term interest-bearing securities	3,561		—		—			3,561
Total available-for-sale investments	$	29,810	$	5	$	(397	)	$	29,418



Types of securities as of December 31, 2017	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair values
U.S. Treasury notes	$	8,313	$	1	$	(72	)	$	8,242
Other government-related debt securities:
U.S.	225		—		(2		)	223
Foreign and other	2,415		18		(11		)	2,422
Corporate debt securities:
Financial	10,089		17		(34		)	10,072
Industrial	9,688		34		(52		)	9,670
Other	1,393		3		(6		)	1,390
Residential-mortgage-backed securities	2,198		—		(30		)	2,168
Other mortgage- and asset-backed securities	2,312		—		(15		)	2,297
Money market mutual funds	3,245		—		—			3,245
Other short-term interest-bearing securities	1,440		—		—			1,440
Total interest-bearing securities	41,318		73		(222		)	41,169
Equity securities	135		14		—			149
Total available-for-sale investments	$	41,453	$	87	$	(222	)	$	41,318

The fair values of available-for-sale investments by location in the Condensed Consolidated Balance Sheets were as follows (in millions):



Condensed Consolidated Balance Sheets locations	September 30, 2018		December 31, 2017
Cash and cash equivalents	$	11,453	$	3,291
Marketable securities	17,965		37,878
Other assets	—		149
Total available-for-sale investments	$	29,418	$	41,318

Cash and cash equivalents in the above table excludes bank account cash of $503 million and $509 million as of September 30, 2018 and December 31, 2017, respectively. Other assets as of December 31, 2017, consisted of equity securities, which are no longer classified as available-for-sale.

As a result of the adoption of the new accounting standard related to the classification and measurement of financial instruments on January 1, 2018, equity investments (except for investments accounted for under the equity method of accounting) are now measured at fair value, with changes in fair value recognized in earnings. These investments were previously measured at fair value, with changes in fair value recognized in AOCI. Accordingly, these securities are no longer classified as available-for-sale and their presentation is not comparable to the presentation as of December 31, 2017. See Equity securities, discussed below, and Note 1, Summary of significant accounting policies.

The fair values of available-for-sale interest-bearing security investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):



Contractual maturities	September 30, 2018		December 31, 2017
Maturing in one year or less	$	17,943	$	6,733
Maturing after one year through three years	2,947		12,820
Maturing after three years through five years	5,585		13,836
Maturing after five years through ten years	1,008		3,263
Maturing after ten years	—		52
Mortgage- and asset-backed securities	1,935		4,465
Total interest-bearing securities	$	29,418	$	41,169

For the three months ended September 30, 2018 and 2017, realized gains on interest-bearing securities were $5 million and $26 million, respectively, and realized losses on interest-bearing securities were $108 million and $12 million, respectively. For the nine months ended September 30, 2018 and 2017, realized gains on interest-bearing securities were $27 million and $91 million, respectively, and realized losses on interest-bearing securities were $379 million and $183 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.

The fair values and gross unrealized losses of available-for-sale investments in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions):



	Less than 12 months					12 months or more
Types of securities as of September 30, 2018	Fair values		Unrealized losses			Fair values		Unrealized losses
U.S. Treasury notes	$	1,795	$	(58	)	$	831	$	(26	)
Other government-related debt securities:
U.S.	43		(1		)	66		(2		)
Foreign and other	855		(38		)	74		(3		)
Corporate debt securities:
Financial	2,262		(74		)	397		(15		)
Industrial	1,970		(68		)	318		(12		)
Other	533		(21		)	13		—
Residential-mortgage-backed securities	673		(27		)	782		(35		)
Other mortgage- and asset-backed securities	135		(4		)	337		(13		)
Total	$	8,266	$	(291	)	$	2,818	$	(106	)



	Less than 12 months					12 months or more
Types of securities as of December 31, 2017	Fair values		Unrealized losses			Fair values		Unrealized losses
U.S. Treasury notes	$	7,728	$	(70	)	$	195	$	(2	)
Other government-related debt securities:
U.S.	188		(1		)	34		(1		)
Foreign and other	1,163		(9		)	115		(2		)
Corporate debt securities:
Financial	5,928		(28		)	462		(6		)
Industrial	5,760		(43		)	612		(9		)
Other	868		(4		)	117		(2		)
Residential-mortgage-backed securities	1,838		(24		)	276		(6		)
Other mortgage- and asset-backed securities	1,777		(12		)	250		(3		)
Total	$	25,250	$	(191	)	$	2,061	$	(31	)

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security. As of September 30, 2018, unrealized losses on available-for-sale investments were due primarily to higher interest rates on that date than at the time the securities were purchased. As of September 30, 2018 and December 31, 2017, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

Equity securities

We held investments in equity securities with readily determinable fair values of $217 million and $149 million as of September 30, 2018 and December 31, 2017, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. As a result of the adoption of the new accounting standard related to the classification and measurement of financial instruments on January 1, 2018, equity investments (except for investments accounted for under the equity method of accounting) are now measured at fair value, with changes in fair value recognized in earnings. These investments were previously measured at fair value, with changes in fair value recognized in AOCI. Accordingly, these securities are no longer classified as available-for-sale and their presentation is not comparable to the presentation as of December 31, 2017. See Available-for-sale investments, discussed above, and Note 1, Summary of significant accounting policies. Gains and losses recognized on equity securities, including gains and losses recognized on sales, were not material for the three and nine months ended September 30, 2018 and 2017.

Limited partnership investments

We held limited partnership investments of $292 million and $213 million as of September 30, 2018 and December 31, 2017, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments are measured by using the net asset values of the underlying investments as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of September 30, 2018, unfunded additional commitments to be made during the next several years for these investments were not material. Gains and losses recognized on our limited partnership investments were not material.

Inventories

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in millions):



	September 30, 2018		December 31, 2017
Raw materials	$	288	$	232
Work in process	1,771		1,668
Finished goods	958		934
Total inventories	$	3,017	$	2,834

Goodwill and other intangible assets

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and other intangible assets

Goodwill

The change in the carrying amount of goodwill was as follows (in millions):



	Nine months ended September 30, 2018
Beginning balance	$	14,761
Addition from K-A acquisition	6
Currency translation adjustment	(83		)
Ending balance	$	14,684

Other intangible assets

Other intangible assets consisted of the following (in millions):



	September 30, 2018							December 31, 2017
	Gross carrying amounts		Accumulated amortization			Intangible assets, net		Gross carrying amounts		Accumulated amortization			Intangible assets, net
Finite-lived intangible assets:
Developed-product-technology rights	$	12,586	$	(7,312	)	$	5,274	$	12,589	$	(6,796	)	$	5,793
Licensing rights	3,771		(1,921		)	1,850		3,275		(1,601		)	1,674
Marketing-related rights	1,285		(982		)	303		1,319		(920		)	399
R&D technology rights	1,159		(860		)	299		1,161		(804		)	357
Total finite-lived intangible assets	18,801		(11,075		)	7,726		18,344		(10,121		)	8,223
Indefinite-lived intangible assets:
In-process research and development	56		—			56		386		—			386
Total other intangible assets	$	18,857	$	(11,075	)	$	7,782	$	18,730	$	(10,121	)	$	8,609

Developed-product-technology rights consist of rights related to marketed products acquired in business combinations. Licensing rights consist primarily of contractual rights acquired in business combinations to receive future milestone, royalty and profit sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. During the nine months ended September 30, 2018, licensing rights increased due to the K-A share acquisition. See Note 3, Business combinations. Marketing-related intangible assets consist primarily of rights related to the sale and distribution of marketed products. R&D technology rights consist of technology used in R&D with alternative future uses.

In-process research and development (IPR&D) consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. During the three months ended September 30, 2018, we discontinued the internal development of a non-key program, resulting in an impairment charge of $330 million, which was recognized in Other operating expenses in the Condensed Consolidated Statements of Income and included in Other items, net, in the Condensed Consolidated Statements of Cash Flows.

All IPR&D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized value, if any, of acquired IPR&D projects may vary from their estimated fair values. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.

During the three months ended September 30, 2018 and 2017, we recognized amortization expense associated with our finite-lived intangible assets of $331 million and $308 million, respectively. During the nine months ended September 30, 2018 and 2017, we recognized amortization expense associated with our finite-lived intangible assets of $983 million and $1.1 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization expense for our finite-lived intangible assets for the remaining three months ending December 31, 2018, and the years ending December 31, 2019, 2020, 2021, 2022 and 2023, are $0.3 billion, $1.3 billion, $1.2 billion, $1.0 billion, $0.9 billion and $0.9 billion, respectively.

Financing arrangements

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Financing arrangements

Our borrowings consisted of the following (in millions):



	September 30, 2018			December 31, 2017
6.15% notes due 2018 (6.15% 2018 Notes)	$	—		$	500
4.375% €550 million notes due 2018 (4.375% 2018 euro Notes)	648			653
5.70% notes due 2019 (5.70% 2019 Notes)	1,000			1,000
1.90% notes due 2019 (1.90% 2019 Notes)	700			700
Floating Rate Notes due 2019	550			550
2.20% notes due 2019 (2.20% 2019 Notes)	1,400			1,400
2.125% €675 million notes due 2019 (2.125% 2019 euro Notes)	783			810
4.50% notes due 2020 (4.50% 2020 Notes)	300			300
2.125% notes due 2020 (2.125% 2020 Notes)	750			750
Floating Rate Notes due 2020	300			300
2.20% notes due 2020 (2.20% 2020 Notes)	700			700
3.45% notes due 2020 (3.45% 2020 Notes)	900			900
4.10% notes due 2021 (4.10% 2021 Notes)	1,000			1,000
1.85% notes due 2021 (1.85% 2021 Notes)	750			750
3.875% notes due 2021 (3.875% 2021 Notes)	1,750			1,750
1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)	1,451			1,501
2.70% notes due 2022 (2.70% 2022 Notes)	500			500
2.65% notes due 2022 (2.65% 2022 Notes)	1,500			1,500
3.625% notes due 2022 (3.625% 2022 Notes)	750			750
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)	713			719
2.25% notes due 2023 (2.25% 2023 Notes)	750			750
3.625% notes due 2024 (3.625% 2024 Notes)	1,400			1,400
3.125% notes due 2025 (3.125% 2025 Notes)	1,000			1,000
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)	870			901
2.60% notes due 2026 (2.60% 2026 Notes)	1,250			1,250
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)	619			642
3.20% notes due 2027 (3.20% 2027 Notes)	1,000			1,000
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)	912			946
6.375% notes due 2037 (6.375% 2037 Notes)	552			552
6.90% notes due 2038 (6.90% 2038 Notes)	291			291
6.40% notes due 2039 (6.40% 2039 Notes)	466			466
5.75% notes due 2040 (5.75% 2040 Notes)	412			412
4.95% notes due 2041 (4.95% 2041 Notes)	600			600
5.15% notes due 2041 (5.15% 2041 Notes)	974			974
5.65% notes due 2042 (5.65% 2042 Notes)	487			487
5.375% notes due 2043 (5.375% 2043 Notes)	261			261
4.40% notes due 2045 (4.40% 2045 Notes)	2,250			2,250
4.563% notes due 2048 (4.563% 2048 Notes)	1,415			1,415
4.663% notes due 2051 (4.663% 2051 Notes)	3,541			3,541
Other notes due 2097	100			100
Unamortized discounts, premiums, issuance costs and fair value adjustments, net	(1,168		)	(929		)
Total carrying value of debt	34,427			35,342
Less current portion	(5,077		)	(1,152		)
Total long-term debt	$	29,350		$	34,190

There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6%, respectively.

Stockholders' equity

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stockholders' equity

Stockholders’ equity

Stock repurchase program

Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):



	2018			2017
	Shares *	Dollars		Shares	Dollars
First quarter	56.4	$	10,787	3.4	$	555
Second quarter	18.2	3,190		6.2	1,006
Third quarter	8.7	1,713		4.4	769
Total stock repurchases	83.4	$	15,690	14.0	$	2,330

* Total shares may not add due to rounding.

In January 2018, the Board of Directors authorized an increase of $10.0 billion available under our stock repurchase program. Repurchase activity for the three months ended March 31, 2018, included 52.1 million shares of our common stock acquired under a tender offer at an aggregate cost of $10.0 billion. In April 2018, the Board of Directors increased the amount authorized under our stock repurchase program by an additional $5.0 billion. As of September 30, 2018, $3.7 billion remained available under our stock repurchase program.

Dividends

In July 2018, March 2018 and December 2017, the Board of Directors declared quarterly cash dividends of $1.32 per share of common stock, which were paid in September 2018, June 2018 and March 2018, respectively. In October 2018, the Board of Directors declared a quarterly cash dividend of $1.32 per share, which will be paid on December 7, 2018.

Accumulated other comprehensive income (loss)

The components of AOCI were as follows (in millions):



	Foreign currency translation			Cash flow hedges			Available-for-sale securities			Other			AOCI
Balance as of December 31, 2017	$	(529	)	$	(6	)	$	(144	)	$	—		$	(679	)
Cumulative effect of change in accounting principle, net of tax⁽¹⁾	—			—			(9		)	—			(9		)
Foreign currency translation adjustments	29			—			—			—			29
Unrealized gains (losses)	—			149			(482		)	—			(333		)
Reclassification adjustments to income	—			(130		)	134			—			4
Other	—			—			—			2			2
Income taxes	—			(13		)	5			—			(8		)
Balance as of March 31, 2018	(500		)	—			(496		)	2			(994		)
Foreign currency translation adjustments	(111		)	—			—			—			(111		)
Unrealized losses	—			(34		)	(106		)	—			(140		)
Reclassification adjustments to income	—			318			115			—			433
Income taxes	—			(61		)	—			—			(61		)
Balance as of June 30, 2018	(611		)	223			(487		)	2			(873		)
Foreign currency translation adjustments	(71		)	—			—			—			(71		)
Unrealized gains (losses)	—			19			(7		)	—			12
Reclassification adjustments to income	—			33			103			—			136
Other	—			—			—			(3		)	(3		)
Income taxes	—			(11		)	1			—			(10		)
Balance as of September 30, 2018	$	(682	)	$	264		$	(390	)	$	(1	)	$	(809	)

^____________


⁽¹⁾	See Note 1, Summary of significant accounting policies, for additional information regarding the adoption on January 1, 2018, of the new accounting standard related to the classification and measurement of financial instruments and the related cumulative effect from the change in accounting principle.

Reclassifications out of AOCI and into earnings were as follows (in millions):



	Three months ended September 30,
Components of AOCI	2018			2017			Condensed Consolidated Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)	$	3		$	(2	)	Product sales
Cross-currency swap contract (losses) gains	(36		)	143			Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	(33		)	140			Income before income taxes
	7			(49		)	Provision for income taxes
	$	(26	)	$	91		Net income
Available-for-sale securities:
Net realized (losses) gains	$	(103	)	$	26		Interest and other income, net
	1			(5		)	Provision for income taxes
	$	(102	)	$	21		Net income



	Nine months ended September 30,
Components of AOCI	2018			2017			Condensed Consolidated Statements of Income locations
Cash flow hedges:
Foreign currency contract (losses) gains	$	(51	)	$	88		Product sales
Cross-currency swap contract (losses) gains	(170		)	514			Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	(221		)	601			Income before income taxes
	47			(213		)	Provision for income taxes
	$	(174	)	$	388		Net income
Available-for-sale securities:
Net realized losses	$	(352	)	$	(70	)	Interest and other income, net
	3			(7		)	Provision for income taxes
	$	(349	)	$	(77	)	Net income

Fair value measurement

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair value measurement

To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:



Level 1	—	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2	—	Valuations for which all significant inputs are observable, either directly or indirectly, other than Level 1 inputs
Level 3	—	Valuations based on inputs that are unobservable and significant to the overall fair value measurement

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.

The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)

Fair value measurement as of September 30, 2018, using:							Total
Assets:
Interest-bearing securities:
U.S. Treasury notes	$	2,626	$	—	$	—	$	2,626
U.S. Treasury bills	5,376		—		—		5,376
Other government-related debt securities:
U.S.	—		109		—		109
Foreign and other	—		1,008		—		1,008
Corporate debt securities:
Financial	—		2,697		—		2,697
Industrial	—		2,578		—		2,578
Other	—		573		—		573
Residential-mortgage-backed securities	—		1,462		—		1,462
Other mortgage- and asset-backed securities	—		473		—		473
Money market mutual funds	8,955		—		—		8,955
Other short-term interest-bearing securities	—		3,561		—		3,561
Equity securities	217		—		—		217
Derivatives:
Foreign currency contracts	—		121		—		121
Cross-currency swap contracts	—		261		—		261
Total assets	$	17,174	$	12,843	$	—	$	30,017

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	49	$	—	$	49
Cross-currency swap contracts	—		306		—		306
Interest rate swap contracts	—		310		—		310
Contingent consideration obligations	—		—		66		66
Total liabilities	$	—	$	665	$	66	$	731



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)

Fair value measurement as of December 31, 2017, using:							Total
Assets:
Interest-bearing securities:
U.S. Treasury notes	$	8,242	$	—	$	—	$	8,242
Other government-related debt securities:
U.S.	—		223		—		223
Foreign and other	—		2,422		—		2,422
Corporate debt securities:
Financial	—		10,072		—		10,072
Industrial	—		9,670		—		9,670
Other	—		1,390		—		1,390
Residential-mortgage-backed securities	—		2,168		—		2,168
Other mortgage- and asset-backed securities	—		2,297		—		2,297
Money market mutual funds	3,245		—		—		3,245
Other short-term interest-bearing securities	—		1,440		—		1,440
Equity securities	149		—		—		149
Derivatives:
Foreign currency contracts	—		6		—		6
Cross-currency swap contracts	—		270		—		270
Interest rate swap contracts	—		10		—		10
Total assets	$	11,636	$	29,968	$	—	$	41,604

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	204	$	—	$	204
Cross-currency swap contracts	—		220		—		220
Interest rate swap contracts	—		61		—		61
Contingent consideration obligations	—		—		69		69
Total liabilities	$	—	$	485	$	69	$	554

Interest-bearing and equity securities

The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment.

Most of our other government-related and corporate debt securities are investment grade and have maturity dates of five years or less from the balance sheet date. Our other government-related debt securities portfolio is composed of securities with weighted-average credit ratings of A– or equivalent by Standard & Poor’s Financial Services LLC (S&P), Moody’s Investors Service, Inc. (Moody’s) or Fitch Ratings, Inc. (Fitch); and our corporate debt securities portfolio has a weighted-average credit rating of A– or equivalent by Fitch, and BBB + or equivalent by S&P or Moody’s. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.

Our residential-mortgage-, other-mortgage- and asset-backed-securities portfolio is composed entirely of senior tranches, with credit ratings of AAA by S&P, Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs.

We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.

Derivatives

All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, the London Interbank Offered Rate (LIBOR), swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. See Note 14, Derivative instruments.

Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 14, Derivative instruments.

Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 14, Derivative instruments.

Contingent consideration obligations

As a result of our business acquisitions, we incurred contingent consideration obligations, as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and are reviewed quarterly by management in our R&D and commercial sales organizations. These inputs include, as applicable, estimated probabilities and timing of achieving specified regulatory and commercial milestones and estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related regulatory and commercial events, or that shorten or lengthen the time required to achieve such events, or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.

Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):



	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Beginning balance	$	72		$	182		$	69		$	179
Addition from K-A acquisition	—			—			45			—
Net changes in valuations	(6		)	(114		)	(48		)	(111		)
Ending balance	$	66		$	68		$	66		$	68

As a result of our acquisition of BioVex Group, Inc., in 2011, we are obligated to pay its former shareholders additional consideration contingent upon achieving certain sales-related milestones with regard to IMLYGIC^®(talimogene laherparepvec).

As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. See Note 3, Business combinations.

During 2017, we decided to discontinue the internal development of AMG 899, an IPR&D asset, and accordingly, reduced from $116 million to zero the related contingent consideration liabilities. The remeasurement of these liabilities is included in Other items, net, in the Condensed Consolidated Statements of Cash Flows.

During the nine months ended September 30, 2018 and 2017, there were no transfers of assets or liabilities between fair value measurement levels. During the nine months ended September 30, 2018 and 2017, there were no material remeasurements to fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to IPR&D assets discussed above, and in Note 10, Goodwill and other intangible assets.

Summary of the fair values of other financial instruments

Cash equivalents

The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.

Borrowings

We estimated the fair values of our borrowings by using Level 2 inputs. As of September 30, 2018 and December 31, 2017, the aggregate fair values of our borrowings were $36.0 billion and $38.6 billion, respectively, and the carrying values were $34.4 billion and $35.3 billion, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Derivative instruments

9 Months Ended

Sep. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative instruments

The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.

During the second quarter of 2018, we adopted early a new accounting standard that amends the accounting and reporting of hedging activities. Certain required disclosures have been made on a prospective basis in accordance with the guidance of the standard. See Note 1, Summary of significant accounting policies.

Cash flow hedges

We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods.

As of September 30, 2018 and December 31, 2017, we had foreign currency forward contracts with notional amounts of $4.5 billion and $4.6 billion, respectively, and foreign currency option contracts with notional amounts of $21 million and $74 million, respectively. We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.

To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.

The notional amounts and interest rates of our cross-currency swaps as of September 30, 2018, were as follows (notional amounts in millions):



	Foreign currency				U.S. dollars
Hedged notes	Notional amounts		Interest rates		Notional amounts		Interest rates
2.125% 2019 euro Notes	€	675	2.125	%	$	864	2.6	%
1.25% 2022 euro Notes	€	1,250	1.25	%	$	1,388	3.2	%
0.41% 2023 Swiss franc Bonds	CHF	700	0.41	%	$	704	3.4	%
2.00% 2026 euro Notes	€	750	2.00	%	$	833	3.9	%
5.50% 2026 pound sterling Notes	£	475	5.50	%	$	747	6.0	%
4.00% 2029 pound sterling Notes	£	700	4.00	%	$	1,111	4.5	%

In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the nine months ended September 30, 2018, and amounts expected to be recognized during the subsequent 12 months are not material.

The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):



	Three months ended September 30,						Nine months ended September 30,
Derivatives in cash flow hedging relationships	2018			2017			2018			2017
Foreign currency contracts	$	41		$	(110	)	$	233		$	(360	)
Cross-currency swap contracts	(22		)	165			(99		)	446
Forward interest rate contracts	—			10			—			13
Total unrealized gains	$	19		$	65		$	134		$	99

The locations in the Condensed Consolidated Statements of Income and the gains and losses reclassified out of AOCI and into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions):



		Three months ended September 30,						Nine months ended September 30,
Derivatives in cash flow hedging relationships	Condensed Consolidated Statements of Income locations	2018			2017			2018			2017
Foreign currency contracts	Product sales	$	3		$	(2	)	$	(51	)	$	88
Cross-currency swap contracts	Interest and other income, net	(36		)	143			(170		)	514
Forward interest rate contracts	Interest expense, net	—			(1		)	—			(1		)
Total realized (losses) gains		$	(33	)	$	140		$	(221	)	$	601

No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness. As of September 30, 2018, the amount expected to be reclassified out of AOCI and into earnings during the next 12 months is $124 million of net losses on our foreign currency and cross-currency swap contracts.

Fair value hedges

To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. The terms of these interest rate swap contracts correspond to the related hedged debt and effectively converted fixed-rate coupons to floating-rate LIBOR-based coupons over the lives of the respective notes. As of September 30, 2018 and December 31, 2017, we had interest rate swap contracts with an aggregate notional amount of $9.45 billion that hedge certain of our long-term debt issuances. The contracts have rates that range from three-month LIBOR plus 0.3% to three-month LIBOR plus 2.0%.

For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.

Net unrealized gains and losses on our outstanding interest rate swap contracts were as follows (in millions):



	Three months ended September 30,						Nine months ended September 30,
Derivatives in fair value hedging relationships	2018			2017			2018			2017
Net unrealized (losses) gains recognized for interest rate swap contracts	$	(44	)	$	(17	)	$	(259	)	$	1
Net unrealized gains (losses) recognized for related hedged debt	$	44		$	17		$	259		$	(1	)

The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):



	Carrying amounts of hedged liabilities⁽¹⁾				Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities⁽²⁾
Condensed Consolidated Balance Sheet locations	September 30, 2018		December 31, 2017		September 30, 2018			December 31, 2017
Current portion of long-term debt	$	2,397	$	500	$	(2	)	$	23
Long-term debt	$	7,859	$	10,516	$	(264	)	$	(11	)

^____________


⁽¹⁾	Current portion of long-term debt includes $1.0 billion and $500 million of carrying value with discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively. Long-term debt includes $137 million and $1.1 billion of carrying value with discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively.


⁽²⁾	Current portion of long-term debt includes $7 million and $23 million of hedging adjustments on discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively. Long-term debt includes $37 million and $40 million of hedging adjustments on discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively.

The following table summarizes the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):



	Three months ended September 30, 2018								Nine months ended September 30, 2018
	Product sales		Interest and other income, net			Interest (expense), net			Product sales			Interest and other income, net			Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income	$	5,510	$	126		$	(355	)	$	16,532		$	519		$	(1,040	)
The effects of cash flow and fair value hedging:
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts	$	3	$	—		$	—		$	(51	)	$	—		$	—
Cross-currency swap contracts	$	—	$	(36	)	$	—		$	—		$	(170	)	$	—
Gains (losses) on fair value hedging relationships—interest rate swap agreements:
Hedged items⁽¹⁾	$	—	$	—		$	48		$	—		$	—		$	278
Derivatives designated as hedging instruments	$	—	$	—		$	(44	)	$	—		$	—		$	(259	)

^__________


⁽¹⁾	The amounts include benefits of $4 million and $19 million related to the amortization of the cumulative amount of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships for the three and nine months ended September 30, 2018, respectively.

Derivatives not designated as hedges

To reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. These exposures are hedged on a month-to-month basis. As of September 30, 2018 and December 31, 2017, the total notional amounts of these foreign currency forward contracts were $243 million and $757 million, respectively. The fair values of these derivatives as of September 30, 2018 and December 31, 2017, were not material.

The location in the Condensed Consolidated Statements of Income and the amounts of gains (losses) recognized in earnings for our derivative instruments not designated as hedging instruments were as follows (in millions):



		Three months ended September 30,					Nine months ended September 30,
Derivatives not designated as hedging instruments	Condensed Consolidated Statements of Income location	2018		2017			2018		2017
Foreign currency contracts	Interest and other income, net	$	11	$	(2	)	$	44	$	12

The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):



	Derivative assets			Derivative liabilities
September 30, 2018	Condensed Consolidated Balance Sheet locations	Fair values		Condensed Consolidated Balance Sheet locations	Fair values
Derivatives designated as hedging instruments:
Foreign currency contracts	Other current assets/ Other assets	$	121	Accrued liabilities/ Other noncurrent liabilities	$	49
Cross-currency swap contracts	Other current assets/ Other assets	261		Accrued liabilities/ Other noncurrent liabilities	306
Interest rate swap contracts	Other current assets/ Other assets	—		Accrued liabilities/ Other noncurrent liabilities	310
Total derivatives designated as hedging instruments		$	382		$	665



	Derivative assets			Derivative liabilities
December 31, 2017	Condensed Consolidated Balance Sheet locations	Fair values		Condensed Consolidated Balance Sheet locations	Fair values
Derivatives designated as hedging instruments:
Foreign currency contracts	Other current assets/ Other assets	$	6	Accrued liabilities/ Other noncurrent liabilities	$	204
Cross-currency swap contracts	Other current assets/ Other assets	270		Accrued liabilities/ Other noncurrent liabilities	220
Interest rate swap contracts	Other current assets/ Other assets	10		Accrued liabilities/ Other noncurrent liabilities	61
Total derivatives designated as hedging instruments		$	286		$	485

Our derivative contracts that were in liability positions as of September 30, 2018, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our, or the surviving entity’s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.

The cash flow effects of our derivative contracts are included within Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows.

Contingencies and commitments	9 Months Ended
Contingencies and commitments	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2017, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 18, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017; and in Notes 14 and 15, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2018 and June 30, 2018, respectively. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in Note 18, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017, or in Notes 14 and 15, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2018 and June 30, 2018, respectively, plaintiffs seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters pending against us described in this filing, in Note 18, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017, or in Notes 14 and 15, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2018 and June 30, 2018, respectively, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Sensipar^® (cinacalcet) Litigation Sensipar^®Abbreviated New Drug Application (ANDA) Patent Litigation On July 27, 2018, the U.S. District Court for the District of Delaware (the Delaware District Court) issued a trial order finding on the infringement claims and defenses in the Amgen Inc. v. Aurobindo Pharma Ltd. et al. consolidated lawsuit that Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) infringe our U.S. Patent No. 9,375,405 (the ’405 Patent) and that the following defendants do not infringe the ’405 Patent: Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Piramal Healthcare UK Limited (Piramal); and Watson Laboratories, Inc., Actavis, Inc. and Actavis Pharma, Inc. (collectively, Watson). On August 24, 2018, the Delaware District Court issued an order dismissing, without prejudice, the invalidity counterclaims of Amneal, Piramal, and Watson and entered judgment of non-infringement of the ’405 Patent in favor of Amneal, Piramal and Watson. On September 20, 2018, Amgen filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On October 9, 2018, the Delaware District Court dismissed, without prejudice, the invalidity counterclaims of Zydus and entered judgment of infringement of the ’405 Patent by Zydus in favor of Amgen, including an order that the effective date of the U.S. Food and Drug Administration (FDA) approval of Zydus’s generic version of Sensipar^® shall be no earlier than the expiry date of our ’405 Patent. On October 11, 2018, Zydus filed a notice of appeal to the Federal Circuit Court and on October 24, 2018, the Federal Circuit Court consolidated the appeals of Zydus and Amgen. On September 7, 2018, Amgen filed a lawsuit in the Delaware District Court for infringement of the ’405 Patent against Emcure Pharmaceuticals Ltd., Heritage Pharmaceuticals Inc., and Heritage Pharma Labs Inc. As previously disclosed, Amgen filed lawsuits in the Delaware District Court and the U.S. District Court for the Middle District of North Carolina (the North Carolina District Court) each against Accord Healthcare, Inc. (Accord) and Intas Pharmaceuticals Ltd. (Intas) for infringement of the ’405 Patent. On September 18, 2018, Accord responded to our lawsuit in the Delaware District Court by denying infringement of the ’405 Patent and alleging that the patent is invalid. On September 20, 2018, Intas was dismissed from the Delaware District Court lawsuit without prejudice by joint stipulation of the parties, and Amgen filed a notice voluntarily terminating the lawsuit filed in the North Carolina District Court. Sensipar^®Pediatric Exclusivity Litigation On October 2, 2018, by agreement between Amgen and the FDA, the U.S. Court of Appeals for the District of Columbia Circuit dismissed Amgen’s appeal of the final judgment that had been ordered by the U.S. District Court for the District of Columbia. NEUPOGEN^® (filgrastim)/ Neulasta^®(pegfilgrastim) Litigation Adello NEUPOGEN^® Patent Litigation On October 3, 2018, Amgen filed an amended complaint in the U.S. District Court for the District of New Jersey (the New Jersey District Court) adding defendants Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals, Inc., to this patent infringement litigation and reducing the number of patents-in-suit from 17 to 4—specifically, U.S. Patent Nos. 8,940,878; 8,952,138; 9,643,997 (the ’997 Patent); and 9,856,287 (the ’287 Patent). On October 17, 2018, Adello Biologics, LLC (Adello) responded to the amended complaint, seeking judgment that our patents-in-suit are not infringed by Adello’s biosimilar filgrastim product and that our patents are invalid. Apotex NEUPOGEN^®/Neulasta^® Patent Litigation On August 7, 2018, Amgen Inc. and Amgen Manufacturing, Ltd. (collectively, Amgen) filed a lawsuit in the U.S. District Court for the Southern District of Florida against Apotex Inc. and Apotex Corp. (collectively, Apotex) for infringement of the ’287 Patent in accordance with the patent provisions of the Biologics Price Competition and Innovation Act. This lawsuit stems from Apotex’s submissions of applications for FDA licensure of a pegfilgrastim product as biosimilar to Amgen’s Neulasta^®and a filgrastim product as biosimilar to Amgen’s NEUPOGEN^®. By its complaint, Amgen seeks, among other remedies, an injunction prohibiting Apotex from infringing the ’287 Patent. On October 1, 2018, Apotex and Adello filed a petition in the United States Patent and Trademark Office requesting that the Patent Trial and Appeal Board institute post grant review proceedings on the ’287 Patent. Pfizer NEUPOGEN^® Patent Litigation On August 9, 2018, defendant Pfizer answered Amgen’s complaint in this patent infringement litigation and included counterclaims seeking a declaratory judgment that Amgen’s ’997 Patent is not infringed by Pfizer’s biosimilar filgrastim product and that our patent is invalid. ENBREL (etanercept) Litigation Sandoz ENBREL Patent Litigation On September 10, 2018, the New Jersey District Court entered an order that the making, using, offering to sell or selling in the United States, or the importation into the United States by Sandoz Inc., Sandoz International GmbH, and Sandoz GmbH (collectively, Sandoz) of Sandoz’s biosimilar etanercept product infringes U.S. Patent Nos. 8,063,182 and 8,163,522. The New Jersey District Court held a bench trial from September 11, 2018 to September 25, 2018 focusing on Sandoz’s challenges to the validity of these patents. Closing arguments are scheduled for November 19, 2018. Hospira EPOGEN^® (epoetin alfa) Patent Litigation Following a jury verdict finding our U.S. Patent No. 5,856,298 (the ’298 Patent) valid and infringed by Hospira Inc. (Hospira) and awarding Amgen $70 million in damages for such infringement, Hospira moved for judgment as a matter of law of noninfringement and invalidity of the ’298 Patent or, in the alternative, for reduction of the damage award or a new trial on the ’298 Patent. On August 27, 2018, the Delaware District Court denied Hospira’s motion and final judgment was entered on September 11, 2018. On October 3, 2018, Hospira filed a notice of appeal to the Federal Circuit Court and on October 15, 2018, Amgen filed a cross-appeal. MVASI^™ (bevacizumab-awwb) Patent Litigation On August 31, 2018, plaintiffs Genentech and City of Hope reduced the number of asserted patents in this patent infringement litigation pending against Amgen from 26 to 8 in accordance with the scheduling order issued by the Delaware District Court. The jury trial has been rescheduled to begin on July 13, 2020. KANJINTI^™ (trastuzumab) Patent Litigation On August 23, 2018, plaintiffs Genentech and City of Hope moved to dismiss Amgen’s unenforceability counterclaims and affirmative defense in this patent infringement litigation pending against Amgen.

Summary of significant accounting policies (Policies)	9 Months Ended
Summary of significant accounting policies (Policies)	Sep. 30, 2018
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation	Basis of presentation The financial information for the three and nine months ended September 30, 2018 and 2017, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2017, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2018 and June 30, 2018.
Principles of consolidation	Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.0 billion and $7.6 billion as of September 30, 2018 and December 31, 2017, respectively.
Revenues	Revenues Adoption of new revenue recognition standard In May 2014, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of January 1, 2018, by applying the modified-retrospective method to those contracts that were not completed as of that date. The results for reporting periods beginning after January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods. See Note 1, Summary of significant accounting policies, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017. Upon adoption, we recorded a net decrease of $25 million to Accumulated deficit due to the cumulative impact of adopting the new standard—with the impact related primarily to the acceleration of deferred revenue, net of related deferred tax impact. The adoption of this new standard had an immaterial impact on our reported total revenues and operating income as compared to what reported amounts would have been under the prior standard, and we expect the impact of adoption in future periods to also be immaterial. Our accounting policies under the new standard were applied prospectively and are described below. See Note 4, Revenues. Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales. Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Taxes collected from customers and remitted to government authorities and that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative expenses in the Condensed Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty estimates are based on historical and forecasted sales trends. Corporate partner revenues are composed primarily of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the research and development (R&D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&D services, (iii) manufacturing services, and/or (iv) commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.
Other recently adopted pronouncements and Other recent accounting pronouncements	Other recently adopted pronouncements In January 2016, the FASB issued a new accounting standard that amends the accounting and disclosures of financial instruments, including a provision requiring that equity investments (except for investments accounted for under the equity method of accounting) be measured at fair value, with changes in fair value recognized in current earnings. With the exception of equity investments that were previously accounted for at cost, a modified-retrospective approach was used to reflect the cumulative effect of adoption as an adjustment to Accumulated deficit as of the beginning of the fiscal year. The new standard will be applied prospectively to investments that were previously accounted for at cost. Upon adoption, on January 1, 2018, we recorded an immaterial adjustment to Accumulated deficit from Accumulated other comprehensive income (loss) (AOCI), which represented the net unrealized gain on all equity investments with a readily determinable fair value as of December 31, 2017. The impact that this new standard has on our Condensed Consolidated Statements of Income after adoption will depend on changes in fair values of equity securities in our portfolio in the future. See Note 8, Investments. In October 2016, the FASB issued a new accounting standard that amends the income tax accounting guidance for intra-entity transfers of assets other than inventory. The new standard requires that entities recognize the income tax consequences of an intercompany transfer of an asset, other than inventory, in the period the transfer occurs. The current exception to defer the recognition of any tax impact on intercompany transfers of inventory until the inventory is sold to a third party remains unaffected. We adopted this standard as of January 1, 2018, and will apply it prospectively to any transaction occurring on or after the adoption date. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, however the impact on our condensed consolidated financial statements in future periods will depend on the facts and circumstances of future transactions. In January 2017, the FASB issued a new accounting standard that changes the definition of a business to assist entities with the evaluation of when a set of assets acquired or disposed of should be considered a business. The new standard requires that an entity evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets; if so, the set of assets would not be considered a business. The new standard also requires that a business include at least one substantive process, and it narrows the definition of outputs. We adopted this standard as of January 1, 2018, and will apply it prospectively. Adoption of this new standard may result in more transactions being accounted for as asset acquisitions versus business combinations; however, the impact on our condensed consolidated financial statements in future periods will depend on the facts and circumstances of future transactions. In August 2017, the FASB issued a new accounting standard that amends the accounting and reporting of hedging activities, which we elected to adopt early during the second quarter of 2018. Among its provisions, the new standard (i) eliminates the separate measurement and reporting of hedge ineffectiveness and (ii) permits an entity to recognize in earnings the initial fair value of an excluded component of a hedging instrument’s fair value under a systematic and rational method over the life of the derivative instrument. In accordance with the transition provisions of the new standard, the separate measurement of ineffectiveness for our cash flow hedging instruments existing as of the date of adoption is required to be eliminated through a cumulative-effect adjustment to Accumulated deficit as of January 1, 2018, the beginning of the fiscal year. The ineffective portions of our cash flow hedges were not material to our previously issued condensed consolidated financial statements. In addition, certain provisions in the guidance require modifications to existing presentation and disclosure requirements on a prospective basis. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 14, Derivative instruments. In March 2018, the FASB issued a new accounting standard to incorporate U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 118 (SAB 118), which addresses accounting implications of major tax reform legislation Public Law No. 115-97, commonly referred to as the Tax Cuts and Jobs Act (the 2017 Tax Act), enacted on December 22, 2017. SAB 118 allows an entity to record provisional amounts during a measurement period not to extend beyond one year from the enactment date and was effective upon issuance. We continue to analyze the 2017 Tax Act and in certain areas have made reasonable estimates of the effects on our condensed consolidated financial statements and tax disclosures. See Note 5, Income taxes. Other recent accounting pronouncements In February 2016, the FASB issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize on the balance sheet the assets and liabilities that arise from leases, including leases classified as operating leases under current GAAP, and disclose qualitative and quantitative information about leasing arrangements. The new standard requires a modified-retrospective approach to adoption and is effective for interim and annual periods beginning on January 1, 2019, but may be adopted earlier. In July 2018, the FASB further amended this standard to allow for a new transition method that provides the option to use the effective date as the date of initial application. We intend to elect this alternative transition method and therefore will not adjust comparative-period financial information. In addition, we intend to elect the package of practical expedients permitted under the transition guidance of the new standard to not reassess prior conclusions related to contracts that are or that contain leases, lease classification and initial direct costs. We expect to adopt this standard beginning in the first quarter of 2019. We do not expect that this standard will have a material impact on our Condensed Consolidated Statements of Income, but we do expect that upon adoption, it will have a material impact on our assets and liabilities on our Condensed Consolidated Balance Sheets. The primary effect of adoption will be the requirement to record right-of-use assets and the corresponding present value of lease obligation liabilities for current operating leases. The actual impact will depend on our lease portfolio at the time of adoption. In addition, the standard requires that we update the systems, processes and controls we use to track, record and account for our lease portfolio. We have selected a lease accounting information system, engaged third-party consultants and are progressing through system implementation. System readiness, including the implementation and functionality of software procured from third-party providers, is essential to enable preparation of the financial information required for this standard. In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020, but may be adopted earlier, beginning on January 1, 2019. With certain exceptions, adjustments are to be applied by using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We are currently evaluating the impact that this new standard will have on our condensed consolidated financial statements.

Business combinations (Tables)

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

Aggregate acquisition date consideration to acquire an entity

The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen’s preacquisition investment consisted of the following (in millions):



	Amount
Total cash paid to Kirin	$	780
Fair value of contingent consideration obligation	45
Loss on settlement of preexisting relationship	(168		)
Total consideration transferred to acquire K-A	657

Fair value of Amgen’s investment in K-A	825
Total acquisition date fair value	$	1,482

Revenues (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):



	Three months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	$	1,242	$	50	$	1,292	$	1,309	$	54	$	1,363
Neulasta^®	897		154		1,051		977		146		1,123
Prolia^®	354		178		532		298		166		464
Aranesp^®	248		229		477		285		231		516
XGEVA®	323		110		433		282		105		387
Sensipar^® / Mimpara^®	330		79		409		373		84		457
EPOGEN^®	252		—		252		264		—		264
Other products	614		450		1,064		509		370		879
Total product sales⁽¹⁾	$	4,260	$	1,250	$	5,510	$	4,297	$	1,156	$	5,453
Other revenues					394						320
Total revenues⁽²⁾					$	5,904					$	5,773



	Nine months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	$	3,544	$	155	$	3,699	$	3,838	$	172	$	4,010
Neulasta^®	2,854		452		3,306		2,962		458		3,420
Prolia^®	1,070		566		1,636		903		491		1,394
Aranesp^®	714		689		1,403		851		711		1,562
XGEVA®	994		336		1,330		872		312		1,184
Sensipar^® / Mimpara^®	1,069		257		1,326		1,052		253		1,305
EPOGEN^®	746		—		746		826		—		826
Other products	1,783		1,303		3,086		1,474		1,051		2,525
Total product sales⁽¹⁾	$	12,774	$	3,758	$	16,532	$	12,778	$	3,448	$	16,226
Other revenues					985						821
Total revenues⁽²⁾					$	17,517					$	17,047

^____________


⁽¹⁾	Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2018 and 2017.


⁽²⁾	Prior-period amounts are not adjusted under the modified-retrospective method of adoption.

Earnings per share (Tables)

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Computation for basic and diluted earnings per share

The computations for basic and diluted EPS were as follows (in millions, except per-share data):



	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Income (Numerator):
Net income for basic and diluted EPS	$	1,859	$	2,021	$	6,466	$	6,243

Shares (Denominator):
Weighted-average shares for basic EPS	645		728		669		733
Effect of dilutive securities	4		5		4		5
Weighted-average shares for diluted EPS	649		733		673		738

Basic EPS	$	2.88	$	2.78	$	9.67	$	8.52
Diluted EPS	$	2.86	$	2.76	$	9.61	$	8.46

Investments (Tables)

9 Months Ended

Sep. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security

The amortized cost, gross unrealized gains, gross unrealized losses and fair values of available-for-sale investments by type of security were as follows (in millions):



Types of securities as of September 30, 2018	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair values
U.S. Treasury notes	$	2,710	$	—	$	(84	)	$	2,626
U.S. Treasury bills	5,376		—		—			5,376
Other government-related debt securities:
U.S.	112		—		(3		)	109
Foreign and other	1,048		1		(41		)	1,008
Corporate debt securities:
Financial	2,786		—		(89		)	2,697
Industrial	2,654		4		(80		)	2,578
Other	594		—		(21		)	573
Residential-mortgage-backed securities	1,524		—		(62		)	1,462
Other mortgage- and asset-backed securities	490		—		(17		)	473
Money market mutual funds	8,955		—		—			8,955
Other short-term interest-bearing securities	3,561		—		—			3,561
Total available-for-sale investments	$	29,810	$	5	$	(397	)	$	29,418



Types of securities as of December 31, 2017	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair values
U.S. Treasury notes	$	8,313	$	1	$	(72	)	$	8,242
Other government-related debt securities:
U.S.	225		—		(2		)	223
Foreign and other	2,415		18		(11		)	2,422
Corporate debt securities:
Financial	10,089		17		(34		)	10,072
Industrial	9,688		34		(52		)	9,670
Other	1,393		3		(6		)	1,390
Residential-mortgage-backed securities	2,198		—		(30		)	2,168
Other mortgage- and asset-backed securities	2,312		—		(15		)	2,297
Money market mutual funds	3,245		—		—			3,245
Other short-term interest-bearing securities	1,440		—		—			1,440
Total interest-bearing securities	41,318		73		(222		)	41,169
Equity securities	135		14		—			149
Total available-for-sale investments	$	41,453	$	87	$	(222	)	$	41,318

Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security

The amortized cost, gross unrealized gains, gross unrealized losses and fair values of available-for-sale investments by type of security were as follows (in millions):



Types of securities as of September 30, 2018	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair values
U.S. Treasury notes	$	2,710	$	—	$	(84	)	$	2,626
U.S. Treasury bills	5,376		—		—			5,376
Other government-related debt securities:
U.S.	112		—		(3		)	109
Foreign and other	1,048		1		(41		)	1,008
Corporate debt securities:
Financial	2,786		—		(89		)	2,697
Industrial	2,654		4		(80		)	2,578
Other	594		—		(21		)	573
Residential-mortgage-backed securities	1,524		—		(62		)	1,462
Other mortgage- and asset-backed securities	490		—		(17		)	473
Money market mutual funds	8,955		—		—			8,955
Other short-term interest-bearing securities	3,561		—		—			3,561
Total available-for-sale investments	$	29,810	$	5	$	(397	)	$	29,418



Types of securities as of December 31, 2017	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair values
U.S. Treasury notes	$	8,313	$	1	$	(72	)	$	8,242
Other government-related debt securities:
U.S.	225		—		(2		)	223
Foreign and other	2,415		18		(11		)	2,422
Corporate debt securities:
Financial	10,089		17		(34		)	10,072
Industrial	9,688		34		(52		)	9,670
Other	1,393		3		(6		)	1,390
Residential-mortgage-backed securities	2,198		—		(30		)	2,168
Other mortgage- and asset-backed securities	2,312		—		(15		)	2,297
Money market mutual funds	3,245		—		—			3,245
Other short-term interest-bearing securities	1,440		—		—			1,440
Total interest-bearing securities	41,318		73		(222		)	41,169
Equity securities	135		14		—			149
Total available-for-sale investments	$	41,453	$	87	$	(222	)	$	41,318

Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets

The fair values of available-for-sale investments by location in the Condensed Consolidated Balance Sheets were as follows (in millions):



Condensed Consolidated Balance Sheets locations	September 30, 2018		December 31, 2017
Cash and cash equivalents	$	11,453	$	3,291
Marketable securities	17,965		37,878
Other assets	—		149
Total available-for-sale investments	$	29,418	$	41,318

Fair values of available-for-sale interest-bearing security investments by contractual maturity



Contractual maturities	September 30, 2018		December 31, 2017
Maturing in one year or less	$	17,943	$	6,733
Maturing after one year through three years	2,947		12,820
Maturing after three years through five years	5,585		13,836
Maturing after five years through ten years	1,008		3,263
Maturing after ten years	—		52
Mortgage- and asset-backed securities	1,935		4,465
Total interest-bearing securities	$	29,418	$	41,169

Available-for-sale securities, continuous unrealized loss position, fair value



	Less than 12 months					12 months or more
Types of securities as of September 30, 2018	Fair values		Unrealized losses			Fair values		Unrealized losses
U.S. Treasury notes	$	1,795	$	(58	)	$	831	$	(26	)
Other government-related debt securities:
U.S.	43		(1		)	66		(2		)
Foreign and other	855		(38		)	74		(3		)
Corporate debt securities:
Financial	2,262		(74		)	397		(15		)
Industrial	1,970		(68		)	318		(12		)
Other	533		(21		)	13		—
Residential-mortgage-backed securities	673		(27		)	782		(35		)
Other mortgage- and asset-backed securities	135		(4		)	337		(13		)
Total	$	8,266	$	(291	)	$	2,818	$	(106	)



	Less than 12 months					12 months or more
Types of securities as of December 31, 2017	Fair values		Unrealized losses			Fair values		Unrealized losses
U.S. Treasury notes	$	7,728	$	(70	)	$	195	$	(2	)
Other government-related debt securities:
U.S.	188		(1		)	34		(1		)
Foreign and other	1,163		(9		)	115		(2		)
Corporate debt securities:
Financial	5,928		(28		)	462		(6		)
Industrial	5,760		(43		)	612		(9		)
Other	868		(4		)	117		(2		)
Residential-mortgage-backed securities	1,838		(24		)	276		(6		)
Other mortgage- and asset-backed securities	1,777		(12		)	250		(3		)
Total	$	25,250	$	(191	)	$	2,061	$	(31	)

Inventories (Tables)

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in millions):



	September 30, 2018		December 31, 2017
Raw materials	$	288	$	232
Work in process	1,771		1,668
Finished goods	958		934
Total inventories	$	3,017	$	2,834

Goodwill and other intangible assets (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill

The change in the carrying amount of goodwill was as follows (in millions):



	Nine months ended September 30, 2018
Beginning balance	$	14,761
Addition from K-A acquisition	6
Currency translation adjustment	(83		)
Ending balance	$	14,684

Schedule of identifiable intangible assets

Other intangible assets consisted of the following (in millions):



	September 30, 2018							December 31, 2017
	Gross carrying amounts		Accumulated amortization			Intangible assets, net		Gross carrying amounts		Accumulated amortization			Intangible assets, net
Finite-lived intangible assets:
Developed-product-technology rights	$	12,586	$	(7,312	)	$	5,274	$	12,589	$	(6,796	)	$	5,793
Licensing rights	3,771		(1,921		)	1,850		3,275		(1,601		)	1,674
Marketing-related rights	1,285		(982		)	303		1,319		(920		)	399
R&D technology rights	1,159		(860		)	299		1,161		(804		)	357
Total finite-lived intangible assets	18,801		(11,075		)	7,726		18,344		(10,121		)	8,223
Indefinite-lived intangible assets:
In-process research and development	56		—			56		386		—			386
Total other intangible assets	$	18,857	$	(11,075	)	$	7,782	$	18,730	$	(10,121	)	$	8,609

Financing arrangements (Tables)

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of Debt Instruments

Our borrowings consisted of the following (in millions):



	September 30, 2018			December 31, 2017
6.15% notes due 2018 (6.15% 2018 Notes)	$	—		$	500
4.375% €550 million notes due 2018 (4.375% 2018 euro Notes)	648			653
5.70% notes due 2019 (5.70% 2019 Notes)	1,000			1,000
1.90% notes due 2019 (1.90% 2019 Notes)	700			700
Floating Rate Notes due 2019	550			550
2.20% notes due 2019 (2.20% 2019 Notes)	1,400			1,400
2.125% €675 million notes due 2019 (2.125% 2019 euro Notes)	783			810
4.50% notes due 2020 (4.50% 2020 Notes)	300			300
2.125% notes due 2020 (2.125% 2020 Notes)	750			750
Floating Rate Notes due 2020	300			300
2.20% notes due 2020 (2.20% 2020 Notes)	700			700
3.45% notes due 2020 (3.45% 2020 Notes)	900			900
4.10% notes due 2021 (4.10% 2021 Notes)	1,000			1,000
1.85% notes due 2021 (1.85% 2021 Notes)	750			750
3.875% notes due 2021 (3.875% 2021 Notes)	1,750			1,750
1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes)	1,451			1,501
2.70% notes due 2022 (2.70% 2022 Notes)	500			500
2.65% notes due 2022 (2.65% 2022 Notes)	1,500			1,500
3.625% notes due 2022 (3.625% 2022 Notes)	750			750
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)	713			719
2.25% notes due 2023 (2.25% 2023 Notes)	750			750
3.625% notes due 2024 (3.625% 2024 Notes)	1,400			1,400
3.125% notes due 2025 (3.125% 2025 Notes)	1,000			1,000
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)	870			901
2.60% notes due 2026 (2.60% 2026 Notes)	1,250			1,250
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)	619			642
3.20% notes due 2027 (3.20% 2027 Notes)	1,000			1,000
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)	912			946
6.375% notes due 2037 (6.375% 2037 Notes)	552			552
6.90% notes due 2038 (6.90% 2038 Notes)	291			291
6.40% notes due 2039 (6.40% 2039 Notes)	466			466
5.75% notes due 2040 (5.75% 2040 Notes)	412			412
4.95% notes due 2041 (4.95% 2041 Notes)	600			600
5.15% notes due 2041 (5.15% 2041 Notes)	974			974
5.65% notes due 2042 (5.65% 2042 Notes)	487			487
5.375% notes due 2043 (5.375% 2043 Notes)	261			261
4.40% notes due 2045 (4.40% 2045 Notes)	2,250			2,250
4.563% notes due 2048 (4.563% 2048 Notes)	1,415			1,415
4.663% notes due 2051 (4.663% 2051 Notes)	3,541			3,541
Other notes due 2097	100			100
Unamortized discounts, premiums, issuance costs and fair value adjustments, net	(1,168		)	(929		)
Total carrying value of debt	34,427			35,342
Less current portion	(5,077		)	(1,152		)
Total long-term debt	$	29,350		$	34,190

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Stockholders' equity (Tables)

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Summary of activity under our stock repurchase program

Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):



	2018			2017
	Shares *	Dollars		Shares	Dollars
First quarter	56.4	$	10,787	3.4	$	555
Second quarter	18.2	3,190		6.2	1,006
Third quarter	8.7	1,713		4.4	769
Total stock repurchases	83.4	$	15,690	14.0	$	2,330

* Total shares may not add due to rounding.

Components of accumulated other comprehensive income

The components of AOCI were as follows (in millions):



	Foreign currency translation			Cash flow hedges			Available-for-sale securities			Other			AOCI
Balance as of December 31, 2017	$	(529	)	$	(6	)	$	(144	)	$	—		$	(679	)
Cumulative effect of change in accounting principle, net of tax⁽¹⁾	—			—			(9		)	—			(9		)
Foreign currency translation adjustments	29			—			—			—			29
Unrealized gains (losses)	—			149			(482		)	—			(333		)
Reclassification adjustments to income	—			(130		)	134			—			4
Other	—			—			—			2			2
Income taxes	—			(13		)	5			—			(8		)
Balance as of March 31, 2018	(500		)	—			(496		)	2			(994		)
Foreign currency translation adjustments	(111		)	—			—			—			(111		)
Unrealized losses	—			(34		)	(106		)	—			(140		)
Reclassification adjustments to income	—			318			115			—			433
Income taxes	—			(61		)	—			—			(61		)
Balance as of June 30, 2018	(611		)	223			(487		)	2			(873		)
Foreign currency translation adjustments	(71		)	—			—			—			(71		)
Unrealized gains (losses)	—			19			(7		)	—			12
Reclassification adjustments to income	—			33			103			—			136
Other	—			—			—			(3		)	(3		)
Income taxes	—			(11		)	1			—			(10		)
Balance as of September 30, 2018	$	(682	)	$	264		$	(390	)	$	(1	)	$	(809	)

^____________


⁽¹⁾	See Note 1, Summary of significant accounting policies, for additional information regarding the adoption on January 1, 2018, of the new accounting standard related to the classification and measurement of financial instruments and the related cumulative effect from the change in accounting principle.

Reclassifications out of accumulated other comprehensive income

Reclassifications out of AOCI and into earnings were as follows (in millions):



	Three months ended September 30,
Components of AOCI	2018			2017			Condensed Consolidated Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)	$	3		$	(2	)	Product sales
Cross-currency swap contract (losses) gains	(36		)	143			Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	(33		)	140			Income before income taxes
	7			(49		)	Provision for income taxes
	$	(26	)	$	91		Net income
Available-for-sale securities:
Net realized (losses) gains	$	(103	)	$	26		Interest and other income, net
	1			(5		)	Provision for income taxes
	$	(102	)	$	21		Net income



	Nine months ended September 30,
Components of AOCI	2018			2017			Condensed Consolidated Statements of Income locations
Cash flow hedges:
Foreign currency contract (losses) gains	$	(51	)	$	88		Product sales
Cross-currency swap contract (losses) gains	(170		)	514			Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	(221		)	601			Income before income taxes
	47			(213		)	Provision for income taxes
	$	(174	)	$	388		Net income
Available-for-sale securities:
Net realized losses	$	(352	)	$	(70	)	Interest and other income, net
	3			(7		)	Provision for income taxes
	$	(349	)	$	(77	)	Net income

Fair value measurement (Tables)

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis

The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)

Fair value measurement as of September 30, 2018, using:							Total
Assets:
Interest-bearing securities:
U.S. Treasury notes	$	2,626	$	—	$	—	$	2,626
U.S. Treasury bills	5,376		—		—		5,376
Other government-related debt securities:
U.S.	—		109		—		109
Foreign and other	—		1,008		—		1,008
Corporate debt securities:
Financial	—		2,697		—		2,697
Industrial	—		2,578		—		2,578
Other	—		573		—		573
Residential-mortgage-backed securities	—		1,462		—		1,462
Other mortgage- and asset-backed securities	—		473		—		473
Money market mutual funds	8,955		—		—		8,955
Other short-term interest-bearing securities	—		3,561		—		3,561
Equity securities	217		—		—		217
Derivatives:
Foreign currency contracts	—		121		—		121
Cross-currency swap contracts	—		261		—		261
Total assets	$	17,174	$	12,843	$	—	$	30,017

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	49	$	—	$	49
Cross-currency swap contracts	—		306		—		306
Interest rate swap contracts	—		310		—		310
Contingent consideration obligations	—		—		66		66
Total liabilities	$	—	$	665	$	66	$	731



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)

Fair value measurement as of December 31, 2017, using:							Total
Assets:
Interest-bearing securities:
U.S. Treasury notes	$	8,242	$	—	$	—	$	8,242
Other government-related debt securities:
U.S.	—		223		—		223
Foreign and other	—		2,422		—		2,422
Corporate debt securities:
Financial	—		10,072		—		10,072
Industrial	—		9,670		—		9,670
Other	—		1,390		—		1,390
Residential-mortgage-backed securities	—		2,168		—		2,168
Other mortgage- and asset-backed securities	—		2,297		—		2,297
Money market mutual funds	3,245		—		—		3,245
Other short-term interest-bearing securities	—		1,440		—		1,440
Equity securities	149		—		—		149
Derivatives:
Foreign currency contracts	—		6		—		6
Cross-currency swap contracts	—		270		—		270
Interest rate swap contracts	—		10		—		10
Total assets	$	11,636	$	29,968	$	—	$	41,604

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	204	$	—	$	204
Cross-currency swap contracts	—		220		—		220
Interest rate swap contracts	—		61		—		61
Contingent consideration obligations	—		—		69		69
Total liabilities	$	—	$	485	$	69	$	554

Changes in carrying amounts of contingent consideration obligations

Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):



	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Beginning balance	$	72		$	182		$	69		$	179
Addition from K-A acquisition	—			—			45			—
Net changes in valuations	(6		)	(114		)	(48		)	(111		)
Ending balance	$	66		$	68		$	66		$	68

Derivative instruments (Tables)

9 Months Ended

Sep. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of notional amounts and interest rates for cross-currency swaps

The notional amounts and interest rates of our cross-currency swaps as of September 30, 2018, were as follows (notional amounts in millions):



	Foreign currency				U.S. dollars
Hedged notes	Notional amounts		Interest rates		Notional amounts		Interest rates
2.125% 2019 euro Notes	€	675	2.125	%	$	864	2.6	%
1.25% 2022 euro Notes	€	1,250	1.25	%	$	1,388	3.2	%
0.41% 2023 Swiss franc Bonds	CHF	700	0.41	%	$	704	3.4	%
2.00% 2026 euro Notes	€	750	2.00	%	$	833	3.9	%
5.50% 2026 pound sterling Notes	£	475	5.50	%	$	747	6.0	%
4.00% 2029 pound sterling Notes	£	700	4.00	%	$	1,111	4.5	%

Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges

The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):



	Three months ended September 30,						Nine months ended September 30,
Derivatives in cash flow hedging relationships	2018			2017			2018			2017
Foreign currency contracts	$	41		$	(110	)	$	233		$	(360	)
Cross-currency swap contracts	(22		)	165			(99		)	446
Forward interest rate contracts	—			10			—			13
Total unrealized gains	$	19		$	65		$	134		$	99

Location in the Condensed Consolidated Statements of Income and the gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges



		Three months ended September 30,						Nine months ended September 30,
Derivatives in cash flow hedging relationships	Condensed Consolidated Statements of Income locations	2018			2017			2018			2017
Foreign currency contracts	Product sales	$	3		$	(2	)	$	(51	)	$	88
Cross-currency swap contracts	Interest and other income, net	(36		)	143			(170		)	514
Forward interest rate contracts	Interest expense, net	—			(1		)	—			(1		)
Total realized (losses) gains		$	(33	)	$	140		$	(221	)	$	601

Derivatives in fair value hedging relationships

Net unrealized gains and losses on our outstanding interest rate swap contracts were as follows (in millions):



	Three months ended September 30,						Nine months ended September 30,
Derivatives in fair value hedging relationships	2018			2017			2018			2017
Net unrealized (losses) gains recognized for interest rate swap contracts	$	(44	)	$	(17	)	$	(259	)	$	1
Net unrealized gains (losses) recognized for related hedged debt	$	44		$	17		$	259		$	(1	)

The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):



	Carrying amounts of hedged liabilities⁽¹⁾				Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities⁽²⁾
Condensed Consolidated Balance Sheet locations	September 30, 2018		December 31, 2017		September 30, 2018			December 31, 2017
Current portion of long-term debt	$	2,397	$	500	$	(2	)	$	23
Long-term debt	$	7,859	$	10,516	$	(264	)	$	(11	)

^____________


⁽¹⁾	Current portion of long-term debt includes $1.0 billion and $500 million of carrying value with discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively. Long-term debt includes $137 million and $1.1 billion of carrying value with discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively.


⁽²⁾	Current portion of long-term debt includes $7 million and $23 million of hedging adjustments on discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively. Long-term debt includes $37 million and $40 million of hedging adjustments on discontinued hedging relationships as of September 30, 2018 and December 31, 2017, respectively.

Summary of amounts of income and expense line items



	Three months ended September 30, 2018								Nine months ended September 30, 2018
	Product sales		Interest and other income, net			Interest (expense), net			Product sales			Interest and other income, net			Interest (expense), net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income	$	5,510	$	126		$	(355	)	$	16,532		$	519		$	(1,040	)
The effects of cash flow and fair value hedging:
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts	$	3	$	—		$	—		$	(51	)	$	—		$	—
Cross-currency swap contracts	$	—	$	(36	)	$	—		$	—		$	(170	)	$	—
Gains (losses) on fair value hedging relationships—interest rate swap agreements:
Hedged items⁽¹⁾	$	—	$	—		$	48		$	—		$	—		$	278
Derivatives designated as hedging instruments	$	—	$	—		$	(44	)	$	—		$	—		$	(259	)

^__________


⁽¹⁾	The amounts include benefits of $4 million and $19 million related to the amortization of the cumulative amount of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships for the three and nine months ended September 30, 2018, respectively.

Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for the derivative instruments not designated as hedging instruments



		Three months ended September 30,					Nine months ended September 30,
Derivatives not designated as hedging instruments	Condensed Consolidated Statements of Income location	2018		2017			2018		2017
Foreign currency contracts	Interest and other income, net	$	11	$	(2	)	$	44	$	12

Fair values of derivatives included in the Condensed Consolidated Balance Sheets

The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):



	Derivative assets			Derivative liabilities
September 30, 2018	Condensed Consolidated Balance Sheet locations	Fair values		Condensed Consolidated Balance Sheet locations	Fair values
Derivatives designated as hedging instruments:
Foreign currency contracts	Other current assets/ Other assets	$	121	Accrued liabilities/ Other noncurrent liabilities	$	49
Cross-currency swap contracts	Other current assets/ Other assets	261		Accrued liabilities/ Other noncurrent liabilities	306
Interest rate swap contracts	Other current assets/ Other assets	—		Accrued liabilities/ Other noncurrent liabilities	310
Total derivatives designated as hedging instruments		$	382		$	665



	Derivative assets			Derivative liabilities
December 31, 2017	Condensed Consolidated Balance Sheet locations	Fair values		Condensed Consolidated Balance Sheet locations	Fair values
Derivatives designated as hedging instruments:
Foreign currency contracts	Other current assets/ Other assets	$	6	Accrued liabilities/ Other noncurrent liabilities	$	204
Cross-currency swap contracts	Other current assets/ Other assets	270		Accrued liabilities/ Other noncurrent liabilities	220
Interest rate swap contracts	Other current assets/ Other assets	10		Accrued liabilities/ Other noncurrent liabilities	61
Total derivatives designated as hedging instruments		$	286		$	485

Summary of significant accounting policies (Details) $ in Millions	9 Months Ended
	Sep. 30, 2018 USD ($) segment	Dec. 31, 2017 USD ($)
Accounting Policies [Abstract]
Number of operating segments \| segment	1
Accumulated depreciation and amortization on property, plant and equipment	$ 8,000	$ 7,600
Change in estimate of sales deductions for prior period sales as a pct of total sales deductions (less than)	1.00%
Sales return provisions as a percentage of gross product sales (less than)	1.00%
New Accounting Pronouncement, Early Adoption [Line Items]
Accumulated deficit	$ (15,987)	(5,072)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] \| Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Accumulated deficit		$ 25

Restructuring (Details) $ in Millions	Sep. 30, 2018 USD ($)
Separation and Other Headcount-related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total costs incurred to date	$ 547
Asset-related Charges [Member]
Restructuring Cost and Reserve [Line Items]
Total costs incurred to date	251
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected pre-tax accounting charges	800
Separation and other headcount-related costs	540
Accelerated depreciation and asset impairment and other related charges	260
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected pre-tax accounting charges	850
Separation and other headcount-related costs	560
Accelerated depreciation and asset impairment and other related charges	$ 290

Business combinations (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 1984
Business Acquisition [Line Items]
Goodwill		$ 14,684	$ 14,761
Kirin-Amgen, Inc. (K-A) [Member]
Business Acquisition [Line Items]
Percentage of voting interests acquired	50.00%
Ownership percentage			50.00%	50.00%
Carrying value of equity method investment			$ 570
Kirin-Amgen, Inc. (K-A) [Member] \| Kirin [Member]
Business Acquisition [Line Items]
Ownership percentage				50.00%
Kirin-Amgen, Inc. (K-A) [Member]
Business Acquisition [Line Items]
Percentage of voting interests acquired	50.00%
Ownership interest in acquiree prior to acquisition (as a percent)	50.00%
Net gain on remeasurement	$ 80
Cash paid	780
Estimated fair values of contingent consideration obligations	45
Fair value of assets acquired, cash	977
Fair value of liabilities assumed, deferred tax liabilities	102
Fair value of assets acquired and liabilities assumed, net other assets and liabilities	131
Goodwill	6
Kirin-Amgen, Inc. (K-A) [Member] \| Licensing Rights [Member]
Business Acquisition [Line Items]
Fair value of assets acquired, licensing rights	$ 470
Weighted average period of amortization	4 years

Business combinations (Aggregate Consideration Paid) (Details) - Kirin-Amgen, Inc. (K-A) [Member] $ in Millions	3 Months Ended
	Mar. 31, 2018 USD ($)
Business Acquisition [Line Items]
Total cash paid to Kirin	$ 780
Fair value of contingent consideration obligation	45
Loss on settlement of preexisting relationship	(168)
Total consideration transferred to acquire K-A	657
Fair value of Amgen’s investment in K-A	825
Total acquisition date fair value	$ 1,482

Revenues (Revenues by Product and by Geographic Area) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) segment	Sep. 30, 2017 USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments \| segment			1
Revenue from External Customer [Line Items]
Total revenues	$ 5,904	$ 5,773	$ 17,517	$ 17,047
Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales	5,510	5,453	16,532	16,226
Product sales [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	4,260	4,297	12,774	12,778
Product sales [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	1,250	1,156	3,758	3,448
Enbrel [Member]
Revenue from External Customer [Line Items]
Total product sales	1,292	1,363	3,699	4,010
Enbrel [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,242	1,309	3,544	3,838
Enbrel [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	50	54	155	172
Neulasta® [Member]
Revenue from External Customer [Line Items]
Total product sales	1,051	1,123	3,306	3,420
Neulasta® [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	897	977	2,854	2,962
Neulasta® [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	154	146	452	458
Prolia® [Member]
Revenue from External Customer [Line Items]
Total product sales	532	464	1,636	1,394
Prolia® [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	354	298	1,070	903
Prolia® [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	178	166	566	491
Aranesp® [Member]
Revenue from External Customer [Line Items]
Total product sales	477	516	1,403	1,562
Aranesp® [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	248	285	714	851
Aranesp® [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	229	231	689	711
XGEVA® [Member]
Revenue from External Customer [Line Items]
Total product sales	433	387	1,330	1,184
XGEVA® [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	323	282	994	872
XGEVA® [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	110	105	336	312
Sensipar® / Mimpara® [Member]
Revenue from External Customer [Line Items]
Total product sales	409	457	1,326	1,305
Sensipar® / Mimpara® [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	330	373	1,069	1,052
Sensipar® / Mimpara® [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	79	84	257	253
EPOGEN® [Member]
Revenue from External Customer [Line Items]
Total product sales	252	264	746	826
EPOGEN® [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	252	264	746	826
EPOGEN® [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	0	0	0	0
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales	1,064	879	3,086	2,525
Other products [Member] \| US [Member]
Revenue from External Customer [Line Items]
Total product sales	614	509	1,783	1,474
Other products [Member] \| ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	450	370	1,303	1,051
Other revenues [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 394	$ 320	$ 985	$ 821

Revenues (Details Textual)	9 Months Ended
Revenues (Details Textual)	Sep. 30, 2018
Minimum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue payment term	30 days
Maximum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue payment term	120 days

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income taxes (Details) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Effective income tax rate	11.20%	15.10%	12.10%	15.40%
Increase in unrecognized tax benefits resulting from tax positions taken during the current period	$ 70		$ 225
Decrease in unrecognized tax benefits resulting tax audit settlement	$ 50

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income (Numerator):
Net income for basic and diluted EPS	$ 1,859	$ 2,021	$ 6,466	$ 6,243
Shares (Denominator):
Weighted-average shares for basic EPS (in shares)	645	728	669	733
Effect of dilutive securities (in shares)	4	5	4	5
Weighted-average shares for diluted EPS (in shares)	649	733	673	738
Basic EPS (in usd per share)	$ 2.88	$ 2.78	$ 9.67	$ 8.52
Diluted EPS (in usd per share)	$ 2.86	$ 2.76	$ 9.61	$ 8.46

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Collaborations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Collaborations (Details) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues	$ 5,904	$ 5,773	$ 17,517	$ 17,047
Other revenues [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues	394	320	985	821
Collaborative arrangement with Novartis Pharma AG [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payment	100		100
Collaborative arrangement with Novartis Pharma AG [Member] \| Other revenues [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues	$ 147	$ 60	$ 295	$ 60

Investments (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Debt securities
Amortized cost	$ 29,810
Gross unrealized gains	5
Gross unrealized losses	(397)
Fair values	29,418	$ 41,169
Equity securities
Amortized cost		135
Gross unrealized gains		14
Gross unrealized losses		0
Fair values		149
Amortized cost		41,453
Gross unrealized gains		87
Gross unrealized losses		(222)
Fair values		41,318
U.S. Treasury notes [Member]
Debt securities
Amortized cost	2,710	8,313
Gross unrealized gains	0	1
Gross unrealized losses	(84)	(72)
Fair values	2,626	8,242
U.S. Treasury bills [Member]
Debt securities
Amortized cost	5,376
Gross unrealized gains	0
Gross unrealized losses	0
Fair values	5,376
Other government-related debt securities - U.S. [Member]
Debt securities
Amortized cost	112	225
Gross unrealized gains	0	0
Gross unrealized losses	(3)	(2)
Fair values	109	223
Other government-related debt securities - Foreign and other [Member]
Debt securities
Amortized cost	1,048	2,415
Gross unrealized gains	1	18
Gross unrealized losses	(41)	(11)
Fair values	1,008	2,422
Corporate debt securities - Financial [Member]
Debt securities
Amortized cost	2,786	10,089
Gross unrealized gains	0	17
Gross unrealized losses	(89)	(34)
Fair values	2,697	10,072
Corporate debt securities - Industrial [Member]
Debt securities
Amortized cost	2,654	9,688
Gross unrealized gains	4	34
Gross unrealized losses	(80)	(52)
Fair values	2,578	9,670
Corporate debt securities - Other [Member]
Debt securities
Amortized cost	594	1,393
Gross unrealized gains	0	3
Gross unrealized losses	(21)	(6)
Fair values	573	1,390
Residential mortgage-backed securities [Member]
Debt securities
Amortized cost	1,524	2,198
Gross unrealized gains	0	0
Gross unrealized losses	(62)	(30)
Fair values	1,462	2,168
Other mortgage- and asset-backed securities [Member]
Debt securities
Amortized cost	490	2,312
Gross unrealized gains	0	0
Gross unrealized losses	(17)	(15)
Fair values	473	2,297
Money market mutual funds [Member]
Debt securities
Amortized cost	8,955	3,245
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	8,955	3,245
Other short-term interest-bearing securities [Member]
Debt securities
Amortized cost	3,561	1,440
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 3,561	1,440
Total interest-bearing securities [Member]
Debt securities
Amortized cost		41,318
Gross unrealized gains		73
Gross unrealized losses		(222)
Fair values		$ 41,169

Investments (Fair Values by Classification) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 11,956	$ 3,800	$ 3,000	$ 3,241
Marketable securities	17,965	37,878
Other assets	1,648	2,119
Total available-for-sale investments	29,418	41,169
Total available-for-sale investments		41,318
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	11,453	3,291
Marketable securities	17,965	37,878
Other assets	0	149
Total available-for-sale investments	$ 29,418
Total available-for-sale investments		$ 41,318

Investments (Available-for-sale Investments) (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 503		$ 503		$ 509
Total realized gains	5	$ 26	27	$ 91
Total realized losses	$ 108	$ 12	$ 379	$ 183

Investments (Fair Values by Contractual Maturity) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 17,943	$ 6,733
Maturing after one year through three years	2,947	12,820
Maturing after three years through five years	5,585	13,836
Maturing after five years through ten years	1,008	3,263
Maturing after ten years	0	52
Mortgage- and asset-backed securities	1,935	4,465
Total available-for-sale investments	$ 29,418	$ 41,169

Investments (Unrealized Losses and Fair Values) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	$ 8,266	$ 25,250
Less than 12 months, Unrealized losses	(291)	(191)
12 months or more, Fair values	2,818	2,061
12 months or more, Unrealized losses	(106)	(31)
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,795	7,728
Less than 12 months, Unrealized losses	(58)	(70)
12 months or more, Fair values	831	195
12 months or more, Unrealized losses	(26)	(2)
Other government-related debt securities - U.S. [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	43	188
Less than 12 months, Unrealized losses	(1)	(1)
12 months or more, Fair values	66	34
12 months or more, Unrealized losses	(2)	(1)
Other government-related debt securities - Foreign and other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	855	1,163
Less than 12 months, Unrealized losses	(38)	(9)
12 months or more, Fair values	74	115
12 months or more, Unrealized losses	(3)	(2)
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	2,262	5,928
Less than 12 months, Unrealized losses	(74)	(28)
12 months or more, Fair values	397	462
12 months or more, Unrealized losses	(15)	(6)
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,970	5,760
Less than 12 months, Unrealized losses	(68)	(43)
12 months or more, Fair values	318	612
12 months or more, Unrealized losses	(12)	(9)
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	533	868
Less than 12 months, Unrealized losses	(21)	(4)
12 months or more, Fair values	13	117
12 months or more, Unrealized losses	0	(2)
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	673	1,838
Less than 12 months, Unrealized losses	(27)	(24)
12 months or more, Fair values	782	276
12 months or more, Unrealized losses	(35)	(6)
Other mortgage- and asset-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	135	1,777
Less than 12 months, Unrealized losses	(4)	(12)
12 months or more, Fair values	337	250
12 months or more, Unrealized losses	$ (13)	$ (3)

Investments (Equity Securities) (Details Textual) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Equity securities	$ 217
Equity securities		$ 149

Investments Investments (Limited Partnership Investments) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Limited Partnership [Member] \| Fair Value Measured at Net Asset Value Per Share [Member]
Net Investment Income [Line Items]
Investments	$ 292	$ 213

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 288	$ 232
Work in process	1,771	1,668
Finished goods	958	934
Total inventories	$ 3,017	$ 2,834

Goodwill and other intangible assets (Goodwill Roll Forward) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2018 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 14,761
Addition from K-A acquisition	6
Currency translation adjustment	(83)
Ending balance	$ 14,684

Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	$ 18,801	$ 18,344
Accumulated amortization	(11,075)	(10,121)
Intangible assets, net	7,726	8,223
Gross carrying amount	18,857	18,730
Accumulated amortization	(11,075)	(10,121)
Intangible assets, net	7,782	8,609
In-process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	56	386
Developed-Product-Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	12,586	12,589
Accumulated amortization	(7,312)	(6,796)
Intangible assets, net	5,274	5,793
Licensing Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	3,771	3,275
Accumulated amortization	(1,921)	(1,601)
Intangible assets, net	1,850	1,674
Marketing-Related Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,285	1,319
Accumulated amortization	(982)	(920)
Intangible assets, net	303	399
R&D Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,159	1,161
Accumulated amortization	(860)	(804)
Intangible assets, net	$ 299	$ 357

Goodwill and other intangible assets (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of IPR&D	$ 330
Amortization charges associated with finite-lived intangible assets	331	$ 308	$ 983	$ 1,100
Total estimated amortization of finite-lived intangible assets for the three months ending December 31, 2018	300		300
Total estimated amortization of finite-lived intangible assets for 2019	1,300		1,300
Total estimated amortization of finite-lived intangible assets for 2020	1,200		1,200
Total estimated amortization of finite-lived intangible assets for 2021	1,000		1,000
Total estimated amortization of finite-lived intangible assets for 2022	900		900
Total estimated amortization of finite-lived intangible assets for 2023	$ 900		$ 900

Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) $ in Millions	Sep. 30, 2018 USD ($)	Sep. 30, 2018 EUR (€)	Sep. 30, 2018 CHF (SFr)	Sep. 30, 2018 GBP (£)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Unamortized discounts, premiums, issuance costs and fair value adjustments, net	$ (1,168)				$ (929)
Total carrying value of debt	34,427				35,342
Less current portion	(5,077)				(1,152)
Total long-term debt	29,350				34,190
Notes [Member] \| 6.15% notes due 2018 (6.15% 2018 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 0				500
Interest rate, stated percentage	6.15%	6.15%	6.15%	6.15%
Notes [Member] \| 4.375% €550 million notes due 2018 (4.375% 2018 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 648				653
Face amount \| €		€ 550,000,000
Interest rate, stated percentage	4.375%	4.375%	4.375%	4.375%
Notes [Member] \| 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	5.70%	5.70%	5.70%	5.70%
Notes [Member] \| 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 700				700
Interest rate, stated percentage	1.90%	1.90%	1.90%	1.90%
Notes [Member] \| Floating Rate Notes due 2019 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 550				550
Notes [Member] \| 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,400				1,400
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Notes [Member] \| 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 783				810
Face amount \| €		€ 675,000,000
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Notes [Member] \| 4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 300				300
Interest rate, stated percentage	4.50%	4.50%	4.50%	4.50%
Notes [Member] \| 2.125% notes due 2020 (2.125% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Notes [Member] \| Floating Rate Notes Due 2020 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 300				300
Notes [Member] \| 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 700				700
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Notes [Member] \| 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 900				900
Interest rate, stated percentage	3.45%	3.45%	3.45%	3.45%
Notes [Member] \| 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	4.10%	4.10%	4.10%	4.10%
Notes [Member] \| 1.85% notes due 2021 (1.85% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	1.85%	1.85%	1.85%	1.85%
Notes [Member] \| 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,750				1,750
Interest rate, stated percentage	3.875%	3.875%	3.875%	3.875%
Notes [Member] \| 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,451				1,501
Face amount \| €		€ 1,250,000,000
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%
Notes [Member] \| 2.70% notes due 2022 (2.70% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 500				500
Interest rate, stated percentage	2.70%	2.70%	2.70%	2.70%
Notes [Member] \| 2.65% notes due 2022 (2.65% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,500				1,500
Interest rate, stated percentage	2.65%	2.65%	2.65%	2.65%
Notes [Member] \| 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Notes [Member] \| 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 713				719
Face amount \| SFr			SFr 700,000,000
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Notes [Member] \| 2.25% notes due 2023 (2.25% 2023 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	2.25%	2.25%	2.25%	2.25%
Notes [Member] \| 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,400				1,400
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Notes [Member] \| 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	3.125%	3.125%	3.125%	3.125%
Notes [Member] \| 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 870				901
Face amount \| €		€ 750,000,000
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Notes [Member] \| 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,250				1,250
Interest rate, stated percentage	2.60%	2.60%	2.60%	2.60%
Notes [Member] \| 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 619				642
Face amount \| £				£ 475,000,000
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Notes [Member] \| 3.20% notes due 2027 (3.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	3.20%	3.20%	3.20%	3.20%
Notes [Member] \| 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 912				946
Face amount \| £				£ 700,000,000
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Notes [Member] \| 6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 552				552
Interest rate, stated percentage	6.375%	6.375%	6.375%	6.375%
Notes [Member] \| 6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 291				291
Interest rate, stated percentage	6.90%	6.90%	6.90%	6.90%
Notes [Member] \| 6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 466				466
Interest rate, stated percentage	6.40%	6.40%	6.40%	6.40%
Notes [Member] \| 5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 412				412
Interest rate, stated percentage	5.75%	5.75%	5.75%	5.75%
Notes [Member] \| 4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 600				600
Interest rate, stated percentage	4.95%	4.95%	4.95%	4.95%
Notes [Member] \| 5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 974				974
Interest rate, stated percentage	5.15%	5.15%	5.15%	5.15%
Notes [Member] \| 5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 487				487
Interest rate, stated percentage	5.65%	5.65%	5.65%	5.65%
Notes [Member] \| 5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 261				261
Interest rate, stated percentage	5.375%	5.375%	5.375%	5.375%
Notes [Member] \| 4.40% notes due 2045 (4.40% 2045 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,250				2,250
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%
Notes [Member] \| 4.563% notes due 2048 (4.563% 2048 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,415				1,415
Interest rate, stated percentage	4.563%	4.563%	4.563%	4.563%
Notes [Member] \| 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 3,541				3,541
Interest rate, stated percentage	4.663%	4.663%	4.663%	4.663%
Notes [Member] \| Other notes due 2097 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 100				$ 100

Financing arrangements (Details Textual) - Notes [Member]	Sep. 30, 2018
4.563% 2048 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%
Effective interest rate	6.30%
4.663% 2051 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%
Effective interest rate	5.60%

Stockholders' equity (Share Repurchase Program) (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended						9 Months Ended
	Mar. 08, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Equity [Abstract]
Stock repurchased, Shares	52.1	8.7	18.2	56.4	4.4	6.2	3.4	83.4	14.0
Stock repurchased		$ 1,713	$ 3,190	$ 10,787	$ 769	$ 1,006	$ 555	$ 15,690	$ 2,330

Stockholders' equity (Details Textual) - USD ($) $ / shares in Units, shares in Millions		1 Months Ended						3 Months Ended						9 Months Ended
	Mar. 08, 2018	Oct. 31, 2018	Sep. 30, 2018	Jul. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Apr. 30, 2018	Jan. 31, 2018
Equity [Abstract]
Stock repurchase program, additional authorized amount																$ 5,000,000,000.0	$ 10,000,000,000.0
Number of shares repurchased	52.1							8.7	18.2	56.4	4.4	6.2	3.4	83.4	14.0
Stock repurchase program, tender offer amount										$ 10,000,000,000
Amount available for stock repurchases under a board approved stock repurchase plan			$ 3,700,000,000					$ 3,700,000,000						$ 3,700,000,000
Dividends paid per share (in usd per share)			$ 1.32		$ 1.32	$ 1.32		$ 1.32			$ 1.15			$ 3.96	$ 3.45
Subsequent Event [Line Items]
Dividends declared per share (in usd per share)				$ 1.32		$ 1.32	$ 1.32
Subsequent Event [Member]
Subsequent Event [Line Items]
Dividends declared per share (in usd per share)		$ 1.32

Stockholders' equity (Components of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period			$ 25,241		$ 25,241
Foreign currency translation adjustments	$ (71)			$ 41	(153)	$ 100
Balance as of end of period	14,349				14,349
Foreign currency translation [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(611)	$ (500)	(529)		(529)
Foreign currency translation adjustments	(71)	(111)	29
Income taxes	0	0	0
Balance as of end of period	(682)	(611)	(500)		(682)
Cash flow hedges [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	223	0	(6)		(6)
Unrealized gains (losses)	19	(34)	149
Reclassification adjustments to income	33	318	(130)
Income taxes	(11)	(61)	(13)
Balance as of end of period	264	223	0		264
Available-for-sale securities [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(487)	(496)	(144)		(144)
Cumulative effect of change in accounting principle, net of tax(1)							$ (9)
Unrealized gains (losses)	(7)	(106)	(482)
Reclassification adjustments to income	103	115	134
Income taxes	1	0	5
Balance as of end of period	(390)	(487)	(496)		(390)
Other [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	2	2	0		0
Unrealized gains (losses)	0	0	0
Other	(3)		2
Balance as of end of period	(1)	2	2		(1)
AOCI [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(873)	(994)	(679)		(679)
Cumulative effect of change in accounting principle, net of tax(1)							$ (9)
Foreign currency translation adjustments	(71)	(111)	29
Unrealized gains (losses)	12	(140)	(333)
Reclassification adjustments to income	(136)	(433)	4
Other	(3)		2
Income taxes	(10)	(61)	(8)
Balance as of end of period	$ (809)	$ (873)	$ (994)		$ (809)

Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ 126	$ 267	$ 519	$ 627
Interest expense, net	(355)	(325)	(1,040)	(972)
Income before income taxes	2,094	2,381	7,360	7,383
Provision for income taxes	(235)	(360)	(894)	(1,140)
Net income	1,859	2,021	6,466	6,243
Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	5,510	5,453	16,532	16,226
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	(33)	140	(221)	601
Provision for income taxes	7	(49)	47	(213)
Net income	(26)	91	(174)	388
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Available-for-sale securities [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(103)	26	(352)	(70)
Provision for income taxes	1	(5)	3	(7)
Net income	(102)	21	(349)	(77)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency contract [Member] \| Cash flow hedges [Member] \| Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	3		(51)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cross-currency swap contract [Member] \| Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(36)		(170)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	(33)	140	(221)	601
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Foreign currency contract [Member] \| Cash flow hedges [Member] \| Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	3	(2)	(51)	88
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Cross-currency swap contract [Member] \| Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(36)	143	(170)	514
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Forward interest rate contracts [Member] \| Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net	$ 0	$ (1)	$ 0	$ (1)

Fair value measurements (Details Textual) - USD ($)	9 Months Ended
Fair value measurements (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Length of time hedged in foreign currency contracts (or less)	3 years
Contingent consideration obligations		$ 0	$ 116,000,000
Long-term debt, fair value	$ 36,000,000,000	38,600,000,000
Carrying value of debt	$ 34,427,000,000	$ 35,342,000,000
Other Government-related and Corporate Debt Securities [Member]
Business Acquisition [Line Items]
Investment maturity period	5 years

Fair value measurement (Changes in Contingent Consideration Obligation) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Business Combination, Contingent Consideration [Roll Forward]
Beginning balance			$ 0	$ 116,000,000
Fair Value, Measurements, Recurring [Member]
Business Combination, Contingent Consideration [Roll Forward]
Beginning balance			69,000,000
Ending balance	$ 66,000,000		66,000,000
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member]
Business Combination, Contingent Consideration [Roll Forward]
Beginning balance	72,000,000	$ 182,000,000	69,000,000	179,000,000
Addition from K-A acquisition	0	0	45,000,000	0
Net changes in valuations	(6,000,000)	(114,000,000)	(48,000,000)	(111,000,000)
Ending balance	$ 66,000,000	$ 68,000,000	$ 66,000,000	$ 68,000,000

Derivative instruments (Details Textual) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps	$ (124)
Rate adjustment to LIBOR on interest rate swap agreements [Member] \| Three-Month LIBOR [Member] \| Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, variable interest rate	0.30%
Rate adjustment to LIBOR on interest rate swap agreements [Member] \| Three-Month LIBOR [Member] \| Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, variable interest rate	2.00%
Derivatives designated as hedging instrument [Member] \| Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	$ 4,500	$ 4,600
Derivatives designated as hedging instrument [Member] \| Foreign currency option contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	21	74
Derivatives designated as hedging instrument [Member] \| Interest rate swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	9,450	9,450
Derivatives not designated as hedging instrument [Member] \| Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	$ 243	$ 757

Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member] € in Millions, £ in Millions, SFr in Millions, $ in Millions	Sep. 30, 2018 USD ($)	Sep. 30, 2018 EUR (€)	Sep. 30, 2018 CHF (SFr)	Sep. 30, 2018 GBP (£)
2.125% 2019 euro Notes [Member]
Derivative [Line Items]
Notional amounts	$ 864	€ 675
1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Notional amounts	1,388	1,250
0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Notional amounts	704		SFr 700
2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Notional amounts	833	€ 750
5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	747			£ 475
4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	$ 1,111			£ 700
Euro Member Countries, Euro \| 2.125% 2019 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.125%	2.125%	2.125%	2.125%
Euro Member Countries, Euro \| 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	1.25%	1.25%	1.25%	1.25%
Euro Member Countries, Euro \| 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.00%	2.00%	2.00%	2.00%
Switzerland, Francs \| 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	0.41%	0.41%	0.41%	0.41%
United Kingdom, Pounds \| 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%	5.50%
United Kingdom, Pounds \| 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.00%	4.00%	4.00%	4.00%
United States of America, Dollars \| 2.125% 2019 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.60%	2.60%	2.60%	2.60%
United States of America, Dollars \| 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.20%	3.20%	3.20%	3.20%
United States of America, Dollars \| 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	3.40%	3.40%	3.40%	3.40%
United States of America, Dollars \| 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%	3.90%
United States of America, Dollars \| 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	6.00%	6.00%	6.00%	6.00%
United States of America, Dollars \| 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.50%	4.50%	4.50%	4.50%

Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	$ 19	$ 65	$ 134	$ 99
Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	41	(110)	233	(360)
Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	(22)	165	(99)	446
Forward interest rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	$ 0	$ 10	$ 0	$ 13

Derivative instruments (Locations and Effective Portions of Gain (Loss) Reclassified out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ 126	$ 267	$ 519	$ 627
Interest expense, net	(355)	(325)	(1,040)	(972)
Income before income taxes	2,094	2,381	7,360	7,383
Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	5,510	5,453	16,532	16,226
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Income before income taxes	(33)	140	(221)	601
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Foreign currency contracts [Member] \| Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	3		(51)
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	(36)		(170)
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Income before income taxes	(33)	140	(221)	601
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member] \| Foreign currency contracts [Member] \| Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	3	(2)	(51)	88
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member] \| Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	(36)	143	(170)	514
Accumulated net gain (loss) from cash flow hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member] \| Forward interest rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense, net	$ 0	$ (1)	$ 0	$ (1)

Derivative instruments Derivative instruments (Fair Value Hedging Relationships) (Details) - Interest expense, net [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative [Line Items]
Net unrealized (losses) gains recognized for interest rate swap contracts	$ (44)	$ (17)	$ (259)	$ 1
Net unrealized gains (losses) recognized for related hedged debt	$ 44	$ 17	$ 259	$ (1)

Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Current portion of long-term debt [Member]
Derivative [Line Items]
Carrying amounts of hedged liabilities	$ 2,397	$ 500
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	(2)	23
Carrying value with discontinued hedging relationships	1,000	500
Hedging adjustments on discontinued hedging relationships	7	23
Long-term debt [Member]
Derivative [Line Items]
Carrying amounts of hedged liabilities	7,859	10,516
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	(264)	(11)
Carrying value with discontinued hedging relationships	137	1,100
Hedging adjustments on discontinued hedging relationships	$ 37	$ 40

Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ 126	$ 267	$ 519	$ 627
Interest expense, net	(355)	(325)	(1,040)	(972)
Amortization of cumulative amount of fair value hedging adjustments for discontinued hedging relationships	4		19
Interest rate swap agreements [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on fair value hedging relationships, Hedged items	48		278
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments	(44)		(259)
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	(36)		(170)
Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	5,510	$ 5,453	16,532	$ 16,226
Product sales [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedges [Member] \| Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	$ 3		$ (51)

Derivative instruments (Locations and Gain (Loss) for Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Foreign currency contracts [Member] \| Interest and other income [Member]
Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for our derivative instruments not designated as hedging instruments
Amount of gain (loss) recognized in interest and other income, net	$ 11	$ (2)	$ 44	$ 12

Derivative instruments (Fair Value of Derivatives) (Details) - Derivatives designated as hedging instrument [Member] - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Assets
Total derivative assets, fair value	$ 382	$ 286
Liabilities
Total derivative liabilities, fair value	665	485
Foreign currency contracts [Member] \| Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	121	6
Foreign currency contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	49	204
Cross-currency swap contracts [Member] \| Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	261	270
Cross-currency swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	306	220
Interest rate swap contracts [Member] \| Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	0	10
Interest rate swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$ 310	$ 61

Contingencies and commitments (Details) $ in Millions				8 Months Ended	9 Months Ended
Contingencies and commitments (Details) $ in Millions	Oct. 03, 2018 patent	Sep. 11, 2018 USD ($)	Aug. 31, 2018 patent	Aug. 30, 2018 patent	Sep. 30, 2018 patent
MVASI Patent Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed			8	26
Adello NEUPOGEN Patent Litigation [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon					17
Adello NEUPOGEN Patent Litigation [Member] \| Subsequent Event [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon	4
Hospira EPOGEN Patent Litigation [Member]
Gain Contingencies [Line Items]
Amount awarded in damages for infringement of patent \| $		$ 70

Fair value measurement (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Assets:
Interest-bearing securities	$ 29,418,000,000		$ 41,169,000,000
Equity securities	217,000,000
Derivatives:
Contingent consideration obligations			0			$ 116,000,000
Fair Value, Measurements, Recurring [Member]
Assets:
Equity securities	217,000,000		149,000,000
Derivatives:
Total assets	30,017,000,000		41,604,000,000
Derivatives:
Contingent consideration obligations	66,000,000		69,000,000
Total liabilities	731,000,000		554,000,000
Fair Value, Measurements, Recurring [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	121,000,000		6,000,000
Derivatives:
Foreign currency and cross-currency swap contracts	49,000,000		204,000,000
Fair Value, Measurements, Recurring [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	261,000,000		270,000,000
Derivatives:
Foreign currency and cross-currency swap contracts	306,000,000		220,000,000
Fair Value, Measurements, Recurring [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate contracts			10,000,000
Derivatives:
Interest rate swap contracts	310,000,000		61,000,000
Fair Value, Measurements, Recurring [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	2,626,000,000		8,242,000,000
Fair Value, Measurements, Recurring [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	5,376,000,000
Fair Value, Measurements, Recurring [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	109,000,000		223,000,000
Fair Value, Measurements, Recurring [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	1,008,000,000		2,422,000,000
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	2,697,000,000		10,072,000,000
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	2,578,000,000		9,670,000,000
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	573,000,000		1,390,000,000
Fair Value, Measurements, Recurring [Member] \| Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	1,462,000,000		2,168,000,000
Fair Value, Measurements, Recurring [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	473,000,000		2,297,000,000
Fair Value, Measurements, Recurring [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	8,955,000,000		3,245,000,000
Fair Value, Measurements, Recurring [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	3,561,000,000		1,440,000,000
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Equity securities	217,000,000		149,000,000
Derivatives:
Total assets	17,174,000,000		11,636,000,000
Derivatives:
Contingent consideration obligations	0		0
Total liabilities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate contracts			0
Derivatives:
Interest rate swap contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	2,626,000,000		8,242,000,000
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	5,376,000,000
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	8,955,000,000		3,245,000,000
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member]
Assets:
Equity securities	0		0
Derivatives:
Total assets	12,843,000,000		29,968,000,000
Derivatives:
Contingent consideration obligations	0		0
Total liabilities	665,000,000		485,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	121,000,000		6,000,000
Derivatives:
Foreign currency and cross-currency swap contracts	49,000,000		204,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	261,000,000		270,000,000
Derivatives:
Foreign currency and cross-currency swap contracts	306,000,000		220,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate contracts			10,000,000
Derivatives:
Interest rate swap contracts	310,000,000		61,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	109,000,000		223,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	1,008,000,000		2,422,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	2,697,000,000		10,072,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	2,578,000,000		9,670,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	573,000,000		1,390,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	1,462,000,000		2,168,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	473,000,000		2,297,000,000
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	3,561,000,000		1,440,000,000
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member]
Assets:
Equity securities	0		0
Derivatives:
Total assets	0		0
Derivatives:
Contingent consideration obligations	66,000,000	$ 72,000,000	69,000,000	$ 68,000,000	$ 182,000,000	$ 179,000,000
Total liabilities	66,000,000		69,000,000
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Derivatives:
Foreign currency and cross-currency swap contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Interest rate swap contracts [Member]
Derivatives:
Interest rate contracts			0
Derivatives:
Interest rate swap contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Money market mutual funds [Member]
Assets:
Interest-bearing securities	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	$ 0		$ 0